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ABSTRACT 
Gonadotropin-releasing hormone (G nRH) and its 
superactive analogues are currently being used in the 
treatment of a number of endocrine disorders, such as 
endometriosis, precocious puberty, infertility and prostatic 
cancer. Selection of these analogues for clinical use have 
been previously based on their activities in animal models. 
This thesis has therefore investigated the binding 
characteristics of the human GnRH receptor, in comparison to 
those of the rat receptor, as well as the activities of a 
number of GnRH analogues for stimulating luteinising hormone 
(LH) and follicle stimulating hormone (FSH) secretion from 
cultured human pituit'ary cells. The establishment of a human 
pituitary bioassay system has further made possible the 
investigation of the direct regulatory roles of GnRH and 
other neuropeptides in man. To date, such studies in man 
have been performed in vivo and are thus complicated by the 
simultaneous interactions of numerous modulators. 
A specific, high affinity receptor for GnRH in human 
pituitaries obtained post-mortem is described. The human 
pituitary GnRH receptor bound GnRH, GnRH agonists 1, 3 and 4 
( [D-Alab ,N""-MeLeu7 ,Pro9 NEt]-GnRH, [Trp7 ]-GnRH and [Hi~]-
GnRH), and GnRH antagonist 1 ([Ac-D-Nal(2) 1 ,D-a-Me-4-
ClPhe2,D-3-Pal3 ~D-Argb,D-Ala10]-GnRH) with similar 
affinities (Kds of 4.81 nM, 0.32nM, 6.60 nM, 9.89 nM and 
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0.32 nM respectively) to those of the rat pituitary (Kess of 
4.71 nM, 0.31 nM, 2.04 nM, 3.16 nM and 0.40 nM 
respectively). GnRH agonist 2 ( [D-Trp6 ,D-Trp7 J-GnRH). GnRH 
antagonists 2 and 3 ([D-pGlu1 ,D-Phe2 ,D-Trp3 • 6 ]-GnRH and [Ac-
D-Nal(2)1 ,D-a-Me-4-ClPhe2 ,D-Trp3 ,D-Arg6,D-Ala1c.J-GnRH) , and 
chicken GnRH II ([His~.Trp 7 ,Tyr0 ]-GnRH), however. were bound 
with much lower affinities by the human receptor (Kd s of 
5.50 nM, 4.21 nM. 11.4 nM and 110.0 nM respectively) than by 
that of the rat (Kess of 0.59 nM, 0.09 nM, 1.00 nM and 28.7 
nM respectively). 
Monovalent and divalent cations affected [12~I]-GnRH 
agonist binding to rat and human pituitary receptors 
differently. In the presence of M9'2· or Ca2 •, binding to the 
human receptor was significantly lower than in the rat. At 
near physiological concentrations, Na· and K· (100 mM and 10 
mM respectively) inhibited [ 12~IJ-GnRH agonist binding to 
the receptors to a similar extent in both species. At 
unphysiological concentrations (10 mM Na+ and 100 mM K+) 
these ions decreased binding to the human pituitary receptor 
to a greater extent than to the rat receptor. 
Using a ligand-immunoblotting technique, the human 
receptor or binding component of the receptor complex was 
found to be of greater molecular size (64,000 daltons) than 
that of the rat (60,000 daltons). 
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active in stimulating LH release from both human and rat 
pituitary cells (0.08 nM and 0.35 nM respectively). GnRH 
agonist 2 and chicken GnRH II also had similar LH-releasing 
activities in the human bioassay (EC~c,s of 0 . 53 nM and 16.8 
nM respectively) as in that of the rat (EC~,:,s of 0.80 nM and 
30.0 nM respectively). From receptor binding data, however, 
it was expected that these two analogues would be less 
active in the human than in the rat. GnRH agonists 3 and 4, 
although bound by the human and rat receptors with similar 
affinities, were more active in releasing LH from human 
pituitary cells than from rat. Further apparent differences 
between the human and the rat are demonstrated by the LH-
inhibiting activities of the GnRH antagonists. GnRH 
antagonists 1, 2 and 3 were less active in the human (IC~c,s 
of 2.60 nM, 72.0 nM and 23.6 nM respectivity) than in the 
rat (I~os of 0.52 nM, 18.7 nM and 0.47 nM respectively). 
The lower activity of antagonists 2 and 3 in the human, 
compared with the rat, were predictable from receptor 
studies, but GnRH antagonist 1 was expected to have a 
similar potency in both species. The biological potencies of 
these analogues for affecting FSH release from the human 
pituitary cells were similar to those for LH. It is thus 
apparent that rat studies are not a valid index for GnRH 
analogue activity in man. 
Stimulation of the human pituitary cells with 100 nM 
GnRH for 44 min resulted in a biphasic release of LH and 
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The results show that the human and rat pituitary GnRH 
receptors have similar binding affinities for GnRH and 
certain GnRH analogues but differ in their binding of at 
least four GnRH analogues, their sensitivity to cationic 
effects on GnRH agonist binding, and in the molecular size 
of the receptor GnRH-binding protein. 
In view of these differences between the human and rat 
pituitary GnRH receptors, a method for culturing human 
pituitary cells from autopsy tissue was established in order 
to investigate the biological potencies of the GnRH 
analogues tested in the receptor binding assays, as well as 
the regulation of gonadotropin secretion by GnRH and other 
neuropeptide hormones at the level of the pituitary. 
The culture of functionally active human pituitary 
cells was validated by virtue of their ability to respond to 
the hypothalamic releasing hormones; GnRH, TRH, CRH and 
GHRH, by releasing LH and FSH, TSH and prolactin, ACTH and 
GH. Inununo-peroxidase staining of the cultured human 
pituitary cells showed that 15.2% of the total cell 
population were LH-containing cells, and 12.3% were FSH-
containing cells. 
The EC~o of GnRH-stimulated LH secretion from human 
pituitary cells was 0 . 95 nM, similar to that found with rat 
pituitary cells (2.00 nM). GnRH agonist 1 was 10-fold more 
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FSH. The initial phase occurred during the first 4 min of 
stimulation, and the second protracted plateau phase 
continued for at least the ensuing 40 min. The kinetics of 
LH and FSH release were identical , with no evidence of 
differential release at any stage. 
GnRH-stimulated LH and 
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activation of protein kinase C is able to elicit LH release. 
In addition to the effects of Ca2 + and phorbol ester, cAMP 
was associated with a dose-dependent increase in LH and FSH 
secretion, suggesting that this cyclic nucleotide also plays 
a role in gonadotropin secretion in man. 
GnRH desensitised the cells to subsequent stimulation 
with GnRH. After an initial 2 h incubation with 0.1-100 nM 
GnRH, LH release during a second 2 h incubation with the 
same doses was reduced by 50-100%. The reduction in FSH 
ranged from 63-92%. Depletion of gonadotropin pools may 
contribute to desensitisation, since total LH and FSH cell 
content decreased 48% and 49%, respectively, after 100 nM 
GnRH stimulation for 4 h. When the initial incubation was 
carried out under Ca2 +-free conditions, the cells still 
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became desensitised to a subsequent stimulation with GnRH, 
although to a lesser degree than in cells incubated in the 
presence of Ca2 +, indicating that the desensitisation 
phenomenon is partly due to depletion of LH and FSH pools 
and partly due to some other Ca2 +-independent mechanism. A 
GnRH antagonist was unable to induce desensitisation 
suggesting that receptor activation is required and not 
merely receptor occupancy. 
Pulsatile administration of GnRH (3 nM for 4 min) to 
cultured human pituitary cells, at frequencies of 45 min, 90 
min and 180 min, resulted in identical secretory profiles of 
LH and FSH. The cells, however, only to responded to 3 
pulses of GnRH before becoming desensitised. These data 
suggest that the cultured human pituitary cells are unable 
to synthesise new stores of LH and FSH. 
Having established a method for culturing human 
pituitary cells the effects of other neuropeptides were 
investigated. 
The human GnRH precursor consists of the GnRH sequence 
followed by a 59-amino acid carboxyl-terminal extension. A 
56-amino acid peptide within this extension (designated GAP) 
has been shown to stimulate gonadotropin release from 
cultured rat pituitary cells. A series of ten overlapping 
peptide fragments were synthesised in our laboratory and 
.. 
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tested for their ability to stimulate LH and FSH release in 
the human pituitary bioassay. Six of the peptides tested 
stimulated gonadotropin secretion from the cultured human 
pituitary cells. All the active peptides were localised to 
the amino-terminal region of the carboxyl-terminal 
extension, and incorporated the decapeptide sequence , Asn-
Leu-Ile-Asp-Ser-Phe-Gln-Glu-Ile-Val, which is regarded as 
the minimal structural requirement delineated for 
gonadotropin-releasing activity. A further flanking sequence 
extending this active region from its carboxyl-terminus was 
found to enhance gonadotropin-releasing activity, although 
the flanking sequence itself was inactive. The gonadotropin 
release stimulated by these peptides was shown to be a dose-
dependent. specific, and Ca2 +-dependent phenomenon which 
occurs via a mechanism involving activation of the GnRH 
receptor, since a GnRH antagonist inhibited the activity and 
the peptides were able to displace [ 1 2 ~11-GnRH agonist from 
human pituitary membranes. 
Substance P (SP) has been implicated as a putative 
' hypothalamic regulatory :peptide in the control of 
gonadotropin secretion. A specific, saturable, high affinity 
receptor for SP is demonstrated in human pituitaries 
obtained post-mortem. The human pituitary SP receptor bound 
SP and two analogues, [D-Tyr°]-SP and [D-Tyr=', NorLeu11 ]-SP, 
with similar affinities (Kds of 17.6 nM, 35.3 nM and 19.3 nM 
respectively). The fragments, SP(3-11), SP(7-10), SP(5-8) 
l. " ~ 
and SP(l-4), had lower affinities for the receptor than SP 
(l<.:ts of 92.4 nM, 286 nM, >1.0 uM, >1.0 uM respective l y). The 
progressive decrease in binding with the removal of amino 
acid residues from the amino- or carboxyl-termini of the 
molecule is similar to that observed in the rat. GnRH and 
TRH did not compete for the SP binding site. SP inhib i ted 
GnRH-stimulated LH secretion from cultured human pituitary 
cells in a dose-dependent manner, while FSH release was 
largely unaffected. These findings suggest that SP may have 
a physiological role in the regulation of LH secretion in 
man. 
These data thus demonstrate that functionally active 
cells can be cultured from human pituitaries obtained post-
mortem, and that the mechanism of GnRH action and the 
regulation of gonadotropin release by other neuropeptides 
closely parallels that in the rat. The human pituitary, 
however, differs from that of the rat in its response to a 
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The major neuroendocrine regulator of gonadotropin 
secretion is gonadotropin-releasing hormone (GnRH). The 
decapeptide hormone, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-
Gly-NH2, is synthesised in the hypothalamic neurons as a 
higher molecular weight prohormonal form (Millar et al., 
1977; Millar et al., 1978; Millar et al. , 1981; Seeburg and 
Adelman, 1984) following which it is processed to GnRH and 
other fragments in the cell bodies or during transportation 
along the axons, such that the processed decapeptide 
predominates in the nerve termini (Millar et al., 1978; 
Rubin et al., 1987). GnRH is secreted irfto the hypophyseal-
portal vessels in a pulsatile manner (Filicori and Crowley, 
1984; Crowley et al., 1985) and reaches the anterior 
pituitary gland where it binds to specific receptors on the 
gonadotrope cells (Clayton and Catt, 1981; Sandow, 1983a), 
resulting in the activation of the second messenger systems, 
namely phospholipid turnover and Ca2 + mobilisation (Conn et 
al., 1987), and finally in the pulsatile secretion of 
luteinising hormone (LH) and follicle stimulating hormone 
(FSH) (Marshall and Kelch, 1986). Following gonadotropin 
release, the hormone-receptor complexes are internalised 
(Jennes et al., 1983; Hazum et al., 1985) where they may 
play a role in such events as receptor recycling, hormone 
degradation and control of LH and FSH gene expression . 
Other putative neuropeptide regulators of gonadotropin 
secretion are substance P. an inhibitor of GnRH-stimulated 
gonadotropin release (Kerdelhue et al .. 1983): and the 
endogenous opioid peptides. several of which have also been 
shown to inhibit gonadotropin secretion at the pituitary 
level (Blank et al .. 1985: Blank et al .. 1986). 
End organ feedback via the gonadal steroids occurs both 
at the hypothalamic level. by altering the firing rates of 
the GnRH neurons (Clarke and Cummins. 1985). and at the 
pituitary level by increasing the responsiveness of the 
gonadotropes to GnRH (Kamel et al .. 1987a). This area is 
covered extensively in the literature (see reviews: Kalra 
and Kalra. 1985: Marshall and Kelch. 1986: Kalra et al., 
1987: Mahesh and Muldoon. 1987) and will not be reviewed 
here. The intention is to address only the neuropeptide 




The mode of secretion of GnRH from the hypothalamus is 
an important factor in the regulation of gonadotropin 
secretion from the anterior pituitary . In earlier years, 
studies on GnRH secretion were difficult due to the fact 
that the peptide is diluted to such a degree in the 
that it is unmeasurable by 
peripheral circulation 
radioimmunoassay (RIA). Indirect methods for assessing GnRH 
secretion were therefore established. These were: ( 1) 
detailed studies on plasma LH levels which provide 
reasonable approximations of GnRH levels in the portal 
vessels; (2) the "ablation-replacement model" which utilises 
the administration of GnRH to GnRH-deficient animals; and 
(3) the "in vitro model" wich uses dispersed pituitary cells 
to investigate the direct effects of GnRH and other putative 
regulators on gonadotropin secretion. 
Measurement of gona.d..otropin 
secretion 
Since the gonadotropins are released from the pituitary 
in a pulsatile manner, this suggests that GnRH is released 
in a similar pattern from the hypothalamus. Thus studies on 
the pulsatile release patterns of LH, which are measurable 
by RIA, give indirect assessments of the regulation of the 
hypothalamic-pituitary axis by GnRH (Santen and Bardin, 
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1973; Reame et al., 1984; Filicori et al., 1986). LH pulses 
vary in frequency during the human menstrual cycle (Filicori 
et al., 1986). The LH interpulse interval decreases during 
the follicular phase from 94 min in early follicular phase 
to 71 min by late follicular phase (Filicori et al., 1986), 
while in the luteal phase it progressively increases from 
103 min 
phase. 
in early luteal phase 







significantly throughout the cycle (Filicori et al., 1986). 
The pulse amplitude declines from early follicular phase to 
midfollicular and rises again by late follicular phase. It 
reaches a maximum in 
progressively decreases 
the early luteal phase and 
until the late luteal phase. These 
observations suggest a varied GnRH pulse frequency during 
the reproductive cycle and changes in GnRH pulse amplitude 
and/or gonadotrope sensitivity to GnRH. 
This method of measuring LH pulsatility as an indirect 
assessment of GnRH pulsatility has two major disadvantages; 
the first being that the model is based on the assumption 
that all the major LH pulses are fully visualised. The 
observed LH interpulse interval has been shown to correlate 
well with the blood sampling interval (Crowley et al., 
1985), which has resulted in a number of conflicting reports 
depending on the sampling times used in the studies. Much of 
this apparent controversy disappears when a blood sampling 
interval of 5 to 10 min is used. This is the optimal time 
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interval in order to visualise all major pulses of LH. The 
second disadvantage of this model is that it relies on the 
assumption that only GnRH is capable of eliciting a pulse of 
LH. This is perhaps reasonable as there is presently little 
evidence for the existance of another gonadotropin-releasing 
factor. More to the point is the converse of this assumption 
that every pulse of GnRH results in a measurable pulse of LH 
being secreted from the gonadotropes. Thus, using this 
approach, small pulses of GnRH which might not be sufficient 
to cause release of LH but could sensitise gonadotropes , 
would be missed. 
Other indirect methods, such as the "ablation-
replacement model" and the "in vitro model", have therefore 
been established, and may be used in conjunction with this 
method in an attempt to maximise physiological information. 
''Ab1a.tion-rep 1a.cement mode 1" 
The "ablation-replacement model" utilises the 
administration of exogenous GnRH to hypothalamic lesioned 
animals (Wildt et al., 1981; Clarke et al., 1986), or humans 
(Spratt et al., 1987; Gross et al., 1987) lacking endogenous 
hypothalamic GnRH. Pulsatile administration of the releasing 
hormone is able to restore full biological function in the 
rhesus monkey (Belchetz et al., 1978) while continuous 
exposure results in desensitisation or refractoriness of the 
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pituitary gonadotrope. This model has been used to 
investigate the significance of altered GnRH pulse frequency 
and amplitude on LH and FSH secretion in the ovariectomised, 
hypothalamic lesioned rhesus monkey (Wildt et al., 1981). 
Increasing the frequency of GnRH administration from the 
physiological 1 pulse/h to 2, 3 or 5 pulses/h resulted in a 
gradual decline of both gonadotropins, while decreasing the 
pulse freq~ency to 1 pulse in 3h led to a decline in plasma 
LH but an increase in FSH (Wildt et al., 1981) . Reduction in 
GnRH pulse amplitude from 1 11g/min to 0.1 11g/min resulted in 
an abrupt decline in gonadotropin levels, while a 10-fold 
increase in amplitude caused a decline in plasma FSH but did 
not affect LH. Alterations in GnRH pulsatility therefore 
appear to be responsible for changes in the LH/FSH ratio 
during the cycle. 
The effect of GnRH pulse frequency on LH and FSH 
secretion in man has · been investigated by administrating 
different regimens of GnRH, in pulsatile fashion, to men 
with idiopathic hypogonadotropic hypogonadism (IHH) (Spratt 
et al., 1987; Gross et al., 1987). It has been shown that 
decreasing the frequency of GnRH pulses from 1 pulse/h to 1 
pulse/2h and 1 pulse/3h, while keeping the total amount of 
GnRH administered constant, resulted in a progressive 
increase in serum FSH levels while serum LH levels were 
unaltered (Gross et al., 1987). Similarly, when the dose per 
pulse was held constant, decreasing the frequency from 1 
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pulse/0.5h to 1 pulse/1.5h again resulted in a selective 
increase in serum FSH levels (Gross et al., 1987). These 
results conflict with a previous report in which decreasing 
the frequency of low dose pulsatile GnRH ad.ministration did 
not cause a preferential rise in serum FSH (Finkelstein et 
al., 1986). However, this particular study was carried out 
using IHH men whose serum testosterone levels had been 
normalised for at least 6 months (Finkelstein et al .. 1986). 
while the above mentioned study was carried out on IHH men 
at a time when serum testosterone and oestradiol levels were 
not normal to minimise the influence of testicular steroids 
(Gross et al., 1987). The importance of the steroid hormone 
milieu on the differential regulation of LH and FSH 
secretion by changes in GnRH pulse frequency have been 
previously demonstrated (Adams et al., 1986). In 
orchidectomised juvenile monkeys in which testosterone 
levels were raised to adult levels using testosterone-
containing silastic capsules, the differential regulation of 
LH and FSH secretion by GnRH pulse frequency was abolished. 
The mechanism for such frequency modulation is at 
present unknown. It has, however, recently been shown that 
pituitary GnRH receptor number is dependent on GnRH pulse 
frequency (Khalid et al., 1987), and thus the differential 
control of LH and FSH secretion may be mediated at the GnRH 

















secreted is not as pronounced in this species as in the 
primate (Clarke et al., 1984). Hourly pulses of GnRH 
restored gonadotropin secretion in these sheep, as has been 
reported in the rhesus monkey (Belchetz et al. , 1978 ) and in 
man (Crowley et al., 1985). Increasing the amplitude of the 
GnRH pulses from 250 ng to 500 ng in sheep caused an 
increase in plasma LH baseline, peak values and pulse 
amplitudes, while there was no significant change in plasma 
FSH over 10 pulses. Decreases in GnRH pulse frequency from 1 
pulse/h to 1 pulse/2h and 1 pulse/4h led to a decrease in 
plasma LH baseline but an increase in LH pulse amplitude. 
This was reversed immediately on reverting pulse frequency 
back to 1 pulse/h. Mean plasma FSH levels rose significantly 
to 111% of values on hourly pulses following the change from 
hourly to 2-hourly pulses. The mean increase in FSH was 
greater after 4 days of 2-hourly pulses but this change was 
rendered non-significant by the variability between 
individual animals. There was no change in FSH levels, 
within 7 days, on reversion back to hourly pulses of GnRH. 
In contrast, in the rhesus monkey plasma FSH levels were 
shown to be inversely related to GnRH pulse frequency (Wildt 
et al., 1981), where on reversion of pulse frequency back to 
1 pulse/h, FSH levels immediately decreased reaching hourly 
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pulse levels within 5 days. It may be necessary to conduct 
these experiments in the sheep for longer durations as is 
suggested by previous studies using adult Soay rams with low 
circulating gonadotropin levels as a result of 12 weeks of 
exposure to long day lengths (Lincoln, 1979a; Lincoln, 
1979b). In these animals, a GnRH pulse frequency of 
approximately 1 pulse/3h caused a progressive rise in plasma 
FSH which reached a maximum after 8 to 10 days (Lincoln, 
1979a). There was no change in mean plasma LH release during 
this period. At the end of the study, when administration of 
GnRH had ceased, the concentration of FSH remained high for 
at least 24 h, decreasing slowly over the ensuing 8 to 14 
days (Lincoln, 1979a; Lincoln, 1979b), while LH pulsatility 
immediately ceased. Thus, while the trends in FSH secretion 
in the sheep are similar to those in the monkey, it is 
apparent that the kinetics are different in that the 
preferential rise in FSH secretion caused by a less than 1 
pulse/h GnRH frequency was more gradual in the sheep than in 
the primate, and the effect was longer lasting on removal of 
the GnRH stimulus. 
The physiological relevance of alterations in GnRH 
pulsatility, and thus the LH/FSH ratios, during the 
reproductive cycle, however, is not clear since it has been 
shown that a constant GnRH pulse frequency administered to 
hypothalamic lesioned rhesus monkeys (Belchetz et al., 1978) 
and sheep (Clarke et al., 1984), and GnRH-deficient women 
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(Crowley et al., 1985) is capable of restoring a fully 
functional reproductive cycle. This latter finding draws 
attention to the major shortfall of this model which is that 
it makes use of the assumption that if an experiment is 
successful in restoring a normal pituitary-gonadal axis then 
this goal must have been achieved by physiological means. 
Studies on LH pulse frequency during the reproductive cycle, 
however, clearly indicate that a constant frequency of GnRH 
pulses is not the physiological norm. Ablation-replacement 
studies of this nature are therefore misleading in that the 
data are easy to misinterpret if not evaluated in the light 
of what is known from other studies using different 
approaches. 
• • I n ""vi t ::i::-o mode 1 • • 
This model involves the use of two cell culture 
techniques: namely the perifusion system and the static 
culture system. In the perifusion system, anterior pituitary 
cells are dispersed, cultured on biocarrier beads, and 
placed in columns where they may be perifused with repeated 
pulses of GnRH, and other secretagogues, at different doses, 
durations and frequencies (Liu and Jackson, 1984: McIntosh 
and McIntosh, 1986: Kamel et al., 1987b). Using perifused 
rat anterior pituitary cells (Liu and Jackson, 1984) it has 
been shown that pulsing with low doses of GnRH (1 and 5 x 
10-10 M) results in the stabilisation of the pituitary cells 
1 1 
and the release of similar amounts of LH in response to each 
sequential GnRH pulse for up to 24 h. In contrast, at high 
doses (10- 8 and 10- 4 M) of GnRH, the pituitary cells 
gradually released less LH with each pulse, suggesting that, 
similar to constant infusion, pulsatile delivery of GnRH at 
high doses can result in desensitisation of the pituitary 
cells to GnRH. This desensitisation may be as a result of 
the uncoupling of post-receptor mediating events, receptor 
down-regulation or depletion of the releasable LH pool. 
A recent study, using perifused sheep pituitary cells, 
was carried out in order to determine whether the release of 
LH and FSH can be controlled differentially by varying the 
patterns of GnRH stimulation alone, free of the effects of 
steroid feedback or other influences from the whole animal 
(McIntosh and McIntosh, 1986). Varying the dose, interval 
and duration of GnRH pulses did not alter the proportions of 
LH and FSH released, in the short-term, from freshly 
dissociated cells. However, as stated previously, in the 
whole animal the alterations in the LH/FSH ratio induced by 
varying the GnRH pulse frequency were only observed after a 
period of 1 to 2 weeks and not within 8 h, which was the 
duration of the in vitro study. There are also other factors 
which may be responsible for the alterations in LH/FSH ratio 
seen in vivo, such as differential clearance from the 
circulation, differential synthesis in intact tissue (no 
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gonadotropin synthesis occurred under the conditions used in 
vitro) or other hormones influencing FSH secretion. 
A disadvantage of the in vitro model is. therefore , 
that only relatively short-term studies can be performed and 
thus studies on the long-term effects of GnRH and other 
hormones must be carried out in the whole anima l, excluding 
as many variables as possible by performing the necessary 
surgical manipulations. 
Static cultures have been used to determine the LH-
releasing potencies of GnRH and other synthetic analogues 
which have potential clinical applications: Investigations 
such as these have shown that the concentration of GnRH 
required to stimulate the release of 50% of maximum 
releasable LH from cultured rat (Loumaye et al., 1982; 
Leiser et al., 1986) and sheep (Millar et al.,1986a; Sower 
et al., 1987) pituitary cells is in the nanomolar range, 
while a number of GnRH agonists have been shown to be 
between 4 and 60 times more potent (Loumaye et al., 1982). 
This technique has also been used to investigate the 
the mechanism of GnRH action (Conn et al., 1987), as well as 
the direct regulatory effects of other hormones, such as 
substance P (Kerdelhue et al., 1983) and the endogenous 
opioids (Blank et al., 1985; Blank et al., 1986). on 
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gonadotropin secretion. These areas will, however, be 
covered in more detail in later sections of this chapter. 
Di~ect meas~~ement of GnRH 
Because of the limitations of the indirect methods for 
assessing GnRH secretion from the hypothalamus, a number of 
techniques have been established for directly measuring GnRH 
in the portal blood of monkeys (Carmel et al., 1976; Carmel 
et al., 1979), man (Carmel et al., 1979; Antunes et al., 
1978) and rats (Sarkar and Fink, 1980). These early studies 
confirmed the hypothesis that GnRH is secreted into the 
portal vessels in a pulsatile fashion. A disadvantage of 
these experiments, however, was that they were performed on 
anaesthetised animals. 
This led to the development of the push-pull perfusion 
system in rats (Levine and Ramirez, 1980; Levine and 
Ramirez, 1982) and sheep (Levine et al., 1982), thus 
allowing the measurement of GnRH in the portal vessels of 
conscious, freely moving animals. The technique comprises 
the implantation of an outer permanent cannula, through 











cerebrospinal fluid is "pushed" through the inner cannula 
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and "pulled" or drawn up between the inner and outer 
cannulae for measurement of GnRH immunoreactivity. 
The development of this technique allowed, for the 
first time, the measurement of GnRH release within the 
mediobasal hypothalamus of conscious rats during the four 
stages of the oestrus cycle and after ovariectomy (Levine 
and Ramirez, 1982). GnRH release rates were measured 
throughout the afternoon and early evening hours of each day 
of the oestrus cycle. This study showed that a biphasic GnRH 
surge occurs on the afternoon of proestrus which may act to 
prime and then stimulate the pituitary gonadotropes thus 
resulting in the LH surge which occurs prior to ovulation. 
During oestrus, GnRH output was low and mostly undetectable, 
while during dioestrus , I and dioestrus I I smal 1 but 
significant rises occurred for a brief period during the 
late afternoon. In long-term ovariectomised rats serum LH 
levels, but not GnRH levels, were increased, suggesting that 
the negative feedback effects of ovarian steroids operate 
primarily at the pituitary level (Levine and Ramirez, 1982). 
In contrast, a recent study which used this technique to 
measure GnRH output at the anterior pituitary of intact and 
castrated male rats (Dluzen and Ramirez, 1987), rather than 
within the hypothalamus (Levine and Ramirez, 1982), has 
demonstrated that GnRH output, fol lowing castration, 
significantly increased due to larger and more frequent 
pulses arriving at the pituitary. This is supported by 
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earlier studies in which GnRH levels in rat portal blood 
were shown to increase after castration (Sherwood and Fink, 
1980). The current hypothesis is, therefore, that following 
castration there is an increased frequency and decreased 
amplitude of individual GnRH signals from discrete loci 
within the mediobasal hypothalamus, but an increased 
synchrony of GnRH signals throughout the hypothalamus 
resulting overall in an increased frequency and amplitude of 
GnRH pulses in the portal blood. 
The temporal relationship between GnRH and LH secretion 
was demonstrated in the ovariectomised sheep, by Levine et 
al., using this push-pull perfusion technique (1982) and, at 
the same time by Clarke and Cummins (1982) using a novel 
approach which involved the insertion of a needle into an 
artificial sinus anterior to the pituitary gland through 
which blood is removed for sampling. The GnRH pulses are 
measured on arrival at the pituitary and therefore reflect 
the sum of all the individual episodes that are secreted 
from the hypothalamus. The results confirmed earlier 
hypotheses in that each LH pulse was synchronous with a GnRH 
pulse. 
More recently, however, it has been shown that apart 
from the "large " amplitude pulses of GnRH that elicit the 
release of LH from the pituitary, there are a number of 
smaller GnRH pulses that are not necessarily associated with 
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pulses of LH into the peripheral blood (Clarke et al .• 1985; 




LH synthesis without release, leading to an 
releasable LH, suggesting that insertion of 
GnRH pulses may modify the pattern of 
pituitary responsiveness to "large" GnRH pulses. 
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GnRH RECEPTORS 
The first step of GnRH action is the binding of the 
neuropeptide to specific, high affinity receptors located on 
the plasma membrane of the gonadotropes in the anterior 
pituitary (Clayton and Catt, 1981). The characterisation of 
pituitary GnRH receptor binding requirements was made 
possible by the development of superactive GnRH analogues 
(agonists) (Schally et al., 1976; Vale et al . , 1976) wi th 
high affinity for the receptor (Perrin et al., 1980a) and 
low susceptibility to proteolytic degradation (Koch et al. , 
1977) . The radioreceptor assay utilises the technique of 
displacing radiolabelled ligand from the receptor with 
increasing concentrations of unlabelled peptide. In early 
studies the labelled ligand used was native GnRH which was 
easily degraded and thus gave artifactual results of 
multiple binding sites with varying affinities for GnRH 
(Spona et al., 1973; Grant et al., 1973). Later studies 
using a GnRH agonist as the radiolabelled ligand, showed 
that the pituitary possessed a single class of saturable, 
high affinity receptors that were specific for GnRH (Clayton 
et al . , 1979; Clayton and Catt, 1980). 
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Homologous regulation of GnRH 
receptors 
The pituitary GnRH receptors are subject to homologous 
regulation by GnRH (Loumaye and Catt, 1982; Clayton 1982). 
This phenomenon is responsible for maintaining gonadotrope 
sensitivity during variations in hormone concentration. 
Fluctuations in GnRH receptor number and cell responsiveness 
have been observed during the rat oestrus cycle, pregnancy 
and lactation (Clayton et al., 1980; Clayton and Catt 1981). 
As mentioned previously, frequency and amplitude of GnRH 
pulsatility also vary during these reproductive stages 
suggesting a direct modulatory role of GnRH pulse frequency 
on receptor number. A recent study using seasonally 
anoestrus ewes has demonstrated that pulsatile GnRH therapy 
results in an up-regulation of GnRH receptors (Khalid et 
al., 1987). In addition, earlier studies, using castrated 
male rats have also shown a direct relationship between GnRH 
pulse frequency and receptor number, which was modulated by 
gonadal steroids (Garcia et al., 1984; Katt et al., 1985). 
In vitro studies, in which the direct effect of GnRH 
was investigated, have demonstrated that following the 
ad.ministration of a physiological dose of GnRH there is an 
initial rapid loss in GnRH binding sites that results from 
internalisation and processing of the receptors and is 
independent of protein synthesis (Loumaye and Catt, 1983). 
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Following this is a protein-synthesis-dependent increase in 
GnRH receptor number (Loumaye and Catt, 1983). This increase 
in receptor number can also be induced by 50mM KCl (i. e. not 
dependent on receptor occupancy) , but not by a GnRH 
antagonist (Loumaye and Catt, 1982; Loumaye and Catt, 1983), 
and must therefore be linked to activation of postreceptor 
events. High concentrations of GnRH (greater than lOOnM) 
causes down-regulation of GnRH receptors, with no subsequent 
rise in receptor number, possibly due to massive 
internalisation and processing of the hormone-receptor 
complexes (Loumaye and Catt, 1982; Zilberstein et al., 
1983) . 
The development of biologically active fluorescent-
labelled analogues of GnRH have allowed direct visualisation 
of the hormone-receptor complex by image-intensified 
fluorescent microscopy (Hazum et al., 1980; Naor et al., 
1981). During the first lOmin the labelled peptide is 
distributed homogeneously on the surface of the 
gonadotropes, following which time patching, capping and 
internalisation occurs. More detailed studies using a 
radiolabelled GnRH analogue and the technique of electron 
microscopic autoradiography, 
initially associated with 
have shown that the label is 
the plasma membrane of the 
gonadotropes, and later with smooth membrane vesicles, 
lysosome-like structures and secretory granules (Hazum et 
al., 1985). The presence of GnRH receptor complexes in 
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secretory granules suggests that a portion of the receptor 
molecules escape degradation and are recyc l ed. 
2 1 
MODE OF ACTION OF GnRH 
Microaggregation of GnRH 
receptors 
The crucial step in GnRH action on gonadotropin 
release, following binding to the receptor , 1s 
microaggregation of the GnRH receptors (Conn et al ., 1982a; 
Conn et al. , 1982b). Internalisation of the hormone receptor 
complex does not appear to be required for initial 
gonadotropin release since LH release occurs within seconds 
of incubation with GnRH while internalisation occurs only 20 
to 30 min later (Hazum et al., 1980; Naor et al., 1981; 
Hazum et al., 1985). Further evidence comes from studies in 
which a GnRH agonist, although immobilised on agarose beads, 
was still able to stimulate LH release from pituitary cells 
with full efficacy (Conn and Hazum, 1981). The presence of 
GnRH binding sites in rat nuclear membrane preparations 
(Millar et al., 1983) suggests that internalisation does 
play some role perhaps involving other intracellular events 
such as receptor recycling, hormone degradation and control 
of LH and FSH gene expression. 
Role of ionic calcium 
Ionic calcium (Ca2 + ) has been shown to fulfill all the 
requirements of a second messenger for GnRH action on 
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gonadotropin secretion. It is well established that GnRH-
stimulated LH release is inhibited substantial l y by the 
removal of extracellular Ca2 .... (Marian and Conn , 1979 ), whi l e 
when Ca2 .... is replaced the cells aga i n respond to the 
releasing hormone (Conn and Rogers . 1979 ). The addition of 
Ca2 + channel blockers, such as D600 , also i nhibit the 
gonadotropin response to GnRH (Borges et a l . , 19 83 ; Bates 
and · Conn, 1984) implicating voltage-sensitive Ca2 .... channels 
in the mechanism of Ca2 .... entry. The converse also holds 
true , whereby addition of a Ca2 ... ·-ionophore, which elevates 
intracellular Ca2 .... levels by smuggling extracellular Ca2 ·+-
across the plasma membrane, stimulates the secretion of LH 
and FSH from cultured rat pituitary cells (Conn et al., 
1979a) . 
The Ca2 + indicator, Quin 2, has been used to directly 
measure intracellular Ca2 + levels before and after 
stimulation with GnRH. Such studies have shown that GnRH 
does cause an increase in the cytosolic Ca2 .... levels of 
gonadotroph enriched cell populations (Clapper and Conn, 
1985). More recent investigations have indicated that the 
initial increase in intracellular Ca2 .... caused by GnRH is due 
to the release of Ca2 + from intracellular stores and is 
independent of extracellular Ca2 ·+- (Limor et al., 1987) . 
Other studies, using cultured chicken pituitary cells, have 
gone so far as to demonstrate that the initial phase of 
GnRH-induced gonadotropin secretion requires not only the 
mobilisation of intracellular Ca2 • but also the influx of 
extracellular Ca2 + via a mechanism other than a voltage-
sensitive Ca2 + channel; possibly a receptor-operated c~· 
channel (Davidson et al., 1988). The second phase of the 
b i phasic gonadotropin response to GnRH involves the 
participation of both a voltage-sensitive Ca2 • channel and 
Ca2 + entry via another route (Davidson et a l ., 1988) 
The evidence thus suggests that activation of the GnRH 
receptor by binding the ligand results in the mobilisation 
of cytosolic Ca2 + and in the opening of a receptor operated 
Ca2 + channel, followed by a voltage-sensitive Ca2 + channel, 
thus resulting in an increase in cytosolic Ca2 + levels and 
finally in gonadotropin release. 
Calmodulin 
Calmodulin is a multifunctional receptor for Ca2 ~· , 
which regulates the activity of many Ca2 • -dependent enzymes, 
including several protein kinases. GnRH has been shown to 
induce a redistribution or translocation of calmodulin from 
the cytosolic fraction to the plasma membrane (Conn et al., 
1981). Subsequent studies have confirmed these findings by 
demonstrating the association of immunoreactive calmodulin 
with GnRH receptor patches (Jennes et al., 1985). This GnRH-
stimulated redistribution of calmodulin appears to be of 
functional significance since several calmodulin inhibitors 
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have been shown to 
gonadotropin secretion 
1987). It therefore 
inhibit the effect of GnRH on 
(Hart et al., 1983; Davidson et al., 
seems likely that the GnRH-induced 
elevation of intracellular Ca2 + enables the formation of a 
Ca2+-calmodulin complex, which in turn regulates the 
activity of a number of enzymes involved in the gonadotropin 
synthesis and secretory processes. 
Ro 1 e of phospholipid turno~er 
Turnover of membrane phospholipids has also been 
implicated in the mechanism of GnRH action (Conn et al., 
1987). It has been shown that phosphatidylinositol (PI) 
turnover is an early step in the mechanism of GnRH action 
(Raymond et al., 1982). PI turnover is believed to precede 
the opening of Ca2 + channels (Michell, 1975) and results in 
the formation of inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG), both of which have second messenger 
functions (Berridge, 1984) . It appears that IP:,; is 
responsible for the mobilisation of Ca2 + since it has been 
shown to stimulate release of Ca2+ from the endoplasmic 
reticulum of permeabilised cells (Berridge, 1984). It has 
also been suggested that 
biproduct of PI turnover, 
Ca2 +-ionophore (Putney et 
phosphatidic 








increased levels of intracellular Ca2 + may interact with 
calmodulin (Conn et al., 1981) and activate phospholipase A2 
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resulting in phospholipid metabolism and the formation of 
free arachidonic acid (Naor et al., 1975). Some arachidonic 
acid metabolites may serve as activators of guanylate 
cyclase resulting in cGMP formation, while others are 
thought to initiate the processes leading to granule fusion 
and gonadotropin secretion (Naor et al., 1984). DAG is an 
activator of the ubiquitous enzyme, protein kinase C (PKC). 
Under resting conditions PKC is found in an inactive form in 
the cell cytosol or loosely associated with membranes. 
Activation by DAG results in tight association of the enzyme 
with the membrane, and a resultant increase in affinity of 
PKC for Ca2 + and phospholipid (Naor et al., 1985). PKC has a 
wide substrate 
phosphorylating a 
involved in the 
gonadotropins. 
specificity and may play a role in 
number of intracellular proteins that are 
secretion and/or synthesis of the 
There appears to be a synergistic effect between the 
PKC and Ca2 + pathways when they are activated simultaneously 
(Harris et al., 1985; Naor and Eli, 1985; Davidson et al., 
1987). This effect is blocked in the presence of calmodulin 
antagonists (Davidson et al., 1987) suggesting that it is a 
calmodulin-dependent process and not a direct effect of Ca2 + 
on PKC. It is hypothesised that a protein phosphorylated by 
PKC interacts synergistically with a calmodulin-dependent 
enzyme to stimulate LH secretion. 
26 
It is therefore apparent that the two major second 
messenger systems, namely PI turnover and Ca2 + mobilisation, 
are closely coupled and that for a full biological response 
of the gonadotropes to GnRH both systems are required. 
Ro1e of cyc1ic n~c1eotides 
The role of cyclic nucleotides in GnRH-stimulated 
gonadotropin release is controversial. Several early reports 
have supported the concept of cyclic nucleotides as 
mediators of GnRH actions (Borgeat et al., 1972; Adams et 
al., 1979) while others have not (Conn et al., 1979b; 
Benoist et al., 1981). Recent studies have shown that GnRH-
stimulated LH release could be facilitated by cAMP (Sundberg 
et al., 1976; Turgeon and Waring, 1986), although cAMP did 
not directly stimulate LH secretion (Sundberg et al., 1976) 
or did so only after a considerable time lag (Magness et 
al., 1981; Turgeon and Waring, 1986). More recently it has 
been shown, that although cAMP was not involved in the acute 
release of LH and FSH, it appeared to play a pivotal but 
indirect role in the protein synthesis dependent phase of 
release by stimulating de novo protein synthesis of the 
gonadotropins and/or the synthesis of proteins that are 
integrally related to the secretion of these hormones 
(Bourne and Baldwin, 1987a; Bourne and Baldwin, 1987b). 
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In view of the initial conflicting reports regarding 
the role of cAMP, it was suggested that cGMP may be the 
intracellular second messenger since GnRH also stimulated an 
increase in intracellular cGMP levels (Snyder et al., 1980). 
The use of an inhibitor of GTP formation, however, 
demonstrated that GnRH-stimulated LH release was not blocked 
in the absence of measurable amounts of cGMP (Naor and Catt, 
1980). The role of this cyclic nucleotide is thus not yet 
clear. 
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OTHER NEUROPEPTIDE REGULATORS 
OF GONADOTROPIN SECRETION 
As is the case in other hormonal systems. gonadotropin 
secretion is under the control of more than one modulator. 
While GnRH is the major regulator. there are a number of 
other neuropeptides such as substance P IKerdelhue et al .. 
1983) and the endogenous opioids (Blank et al .. 1985; Blank 
et al .. 1986) which also have a direct effect on 
gonadotropin secretion from the pituitary. 
S~bstance P 
Substance P (SP) is an undecapeptide which, although 
first described in the gastrointestinal tract (Von Euler and 
Gaddum. 19311. has since been shown to be widely distributed 
within the peripheral and central nervous systems of mammals 
(Nicholl et al .. 1980: Aronin et al .. 1983: Pernow, 1983). 
Fluctuations in hypothalamic SP occur during the rat oestrus 
cycle (Kerdelhue et al., 1982). and it has been shown to 
affect the release of gonadotropins IKerdelhue et al .. 1978: 
Vijayan and Mccann. 1979) and prolactin (Vijayan and Mccann, 
1979; Eckstein et al., 1980) in vivo , thus suggesting that 
the peptide plays a role in control of reproductive 
function. More recently. SP has been found to inhibit GnRH-
stimulated LH and FSH release from cultured rat anterior 
pituitary cells IKerdelhue et al .. 1979: Kerdelhue et al .. 
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1982) and to bind to specific, high affinity binding sites 
in rat anterior pituitary membranes (Kerdelhue et al., 1982; 
Kerdelhue et al., 1985), implicating a direct modulatory 
role for SP on gonadotropin secretion. Further evidence for 
a physiological role of SP comes from in vivo studies which 
have demonstrated that after administration of SP antisera 
to rats, there was an increase in LH and FSH (Kerdelhue et 
al., 1979; Kerdelhue et al., 1982). The administration of SP 
to female rhesus 
gonadotropins, while 
prolactin secretion 
monkeys, however, had no effect on 
it induced a significant increase in 
(Eckstein et al., 1980) . This suggests 
that the peptide may not have a role in the control of 
reproduction in primates. It would therefore be of interest 
to determine whether SP exerts an effect on gonadotropin 
secretion in man. 
Endogenous op101d peptides 
Opioid agonists when administered acutely inhibit 
gonadotropin secretion in man (Azizi et al., 1973; Santen et 
al., 1975) and other species (Cicero et al., 1979). These 
acute effects of opioids on LH and FSH release are mediated 
mainly at the hypothalamic level (Wilkes and Yen, 1981). 
However, in view of the fact that the anterior pituitary has 
a 250-fold greater concentration of B-endorphin than the 
hypothalamus (Bloom et al., 1978), a number of studies have 
been carried out to investigate the possible direct effects 
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of opioid peptides on gonadotropin secretion from pituitary 
cells. The results of these investigations have shown that 
gamma-endorphin (Matteri and Moberg, 1985), human B-
endorphin (Matteri and Moberg, 1985; Blank et al., 1986; 
Snchez-Franco and Cacicedo, 1986) and morphine (Blank et 
al., 1985; Blank et al., 1986) are capable of directly 
inhibiting GnRH-stimulated gonadotropin secretion at the 
pituitary level. Specific, saturable opiate binding sites 
have also been described in pituitary tissue (Blank et al., 
1985; Blank et al., 1986), suggesting that the opiates exert 
their effects by binding to specific receptors on the 
gonadotropes. These 
opioids at the 
direct inhibitory actions of endogenous 
pituitary level may be of particular 
importance in alterations of reproductive function during 
times of stress, strenuous athletic exercise and other 
conditions accompanied by secretion of large amounts of 
pituitary opioids. 
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OBJECTIVES OF THIS STUDY 
GnRH and its superactive analogues are being used 
clinically in the treatment of various endocrine disorders, 
such as endometriosis, precocious puberty, infertility and 
prostatic cancer, as well as being investigated as possible 
contraceptives (Sandow 1983b). To date , these superactive 
analogues have been selected for clinical use on the basis 
of their relative activities in rats. The first objective of 
the present study was therefore to determine whether the 
human and rat pituitary receptors have similar properties, 
using the radioreceptor assay technique, thus vindicating 
the use of rat receptor binding studies as a reasonable 
index of GnRH analogue activity in man. 
The second objective of this study was to establish a 
system for culturing human pituitary cells from post-mortem 
tissue in order to investigate the neuropeptide regulation 
of gonadotropin secretion, at the pituitary level, in man. 
In particular, the biological potencies of a number of GnRH 
analogues and the mechanism of GnRH-stimulated gonadotropin 
secretion was investigated, as well as the direct regulatory 
effects of substance Panda range of novel peptides, which 
are potentially processed from the GnRH precursor. To date, 
such studies have been restricted to laboratory and domestic 
animals. In vivo studies on hypothalamic peptide regulation 
of pituitary hormone secretion are complicated by the 
simultaneous interaction of various modulators, such as 
neurotransmitters, steroids and other hormones. In vitro 
studies using cultured pituitary cells are , therefore, 
advantageous in that the direct effects of i ndividual 
hormones may be investigated. 
CHAPTER 2 




The initial step in GnRH action is the binding of the 
peptide to specific receptors on the plasma membrane of 
pituitary gonadotropes. The binding affinity of GnRH 
analogues for rat receptors is a good index of gonadotropin-
releasing activity of these analogues (Clayton and Catt, 
1980; Clayton and Catt, 1981: Loumaye et al., 1982) and 
receptor binding characteristics are, therefore, predictors 
of biological activity. The specificity and binding affinity 
of the human GnRH receptor, however, are unknown. The 
characterisation of the human receptor may have important 
implications since GnRH and its superactive analogues are 
being used clinically in the treatment of endometriosis, 
precocious puberty, infertility, and prostatic cancer, as 
well as being investigated as possible contraceptives 
(Sandow, 1983b). For this reason it is of value to determine 
whether the human and rat GnRH receptors have similar 
properties, thus vindicating the use of rat receptor binding 
assays as a reasonable index of GnRH analogue activity in 
the selection of superactive analogues for use in human 
studies. I have therefore developed methodology for 
investigating the GnRH receptor in membranes isolated from 
human pituitaries obtained at autopsy and compared the 
characteristics with those of the rat pituitary receptor. 
MATERIALS AND METHODS 
Hor-mones 
Synthetic GnRH was obtained from Bachem Feinchemikalien 
AG (Bubendorf, Switzerland); GnRH agonist 1, (D-Ala6 ,N~-
MeLeu7 ,Pro9 NEt)-GnRH , from Dr J E Rivier, The Salk Institute 
(San Diego, CA); GnRH agonist 2, (D-Trp6 ,Trp7 )-GnRH, from Dr 
R deL Milton, University of Cape Town Medical School (Cape 
Town, South Africa) ; GnRH agonist 3, (Trp7 ) -GnRH, from Dr R 
deL Milton; GnRH agonist 4, (His~ )-GnRH, from Dr R deL 
Milton; GnRH antagonist 1, (Ac-D-Nal(2) 1 ,D-a-Me-4-ClPhe2 ,D-
3-Pal3 ,D-Arg6,D-Ala10NH2 )-GnRH, from Dr R Roeske, Indiana 
University School of Medicine (Indianapolis, IN); GnRH 
antagonist 2, (D-pGlu1 ,D-Phe2 ,D-Trp3 • 6 )-GnRH, from Dr J E 
Rivier; GnRH antagonist .3, (Ac-D-Nal(2) 1 ,D-a-Me-4-ClPhe2 ,D-
Trp3 ,D-Arg0,D-Ala10Nl6)-GnRH, from Dr R Roeske; chicken GnRH 
II , (His~,Trp7 ,Tyr9 )-GnRH, from Dr R deL Milton; GnRH 1-5 
from Dr R deL Milton; (D-Ala1 )-somatostatin-14 from Dr DH 
Coy, Tulane University (New Orleans, LA); and synthetic 
porcine TRH from Bechman Instruments Inc. (Palo Alto, CA). 
B ind.. i ng st l...l.d.. i es 
Human anterior pituitaries were obtained from nine 
healthy women (25-35 yr of age) between 12 and 48h after 
accidental death. They were immediately snap frozen in 
liquid nitrogen and stored at -70mc until use. The membranes 
were prepared by homogenising the tissue in buffer A (10 mM 
Tris HCl. 1 mM EDTA, 1 mM dithiothreitol. 0.1% BSA. pH7.4), 
centrifuging at 1000 x g for 15 min. and centrifuging the 
resulting supernatant for 30 min at 10.000 x g (Hazum . 
1981a). The membrane pellet was resuspended in the same 
buffer. Rat anterior pituitaries were obtained from adult 
male Long-Evans rats (350-450 g) 
described for the human. 
and were processed as 
All binding studies were performed in triplicate in 
buffer A. Unlabelled peptides (50 ul) and 50 u 1 label led 
peptide (60.000-70.000 cpm) were added to 400 ul membrane 
suspension (0.1 human or 0.4 rat pituitary equivalents/ml), 
mixed . and incubated for 150 min at 4°C. The contents of 
these tubes were transferred with 3 ml buffer B (0.04 M 
sodium phosphate. 0.15 M NaCl, 1.0% BSA. pH 7.4) onto 
Whatman GF/C filters (presoaked for 24 h in this buffer) and 
the filters washed three times with 3 ml buffer B. Bound 
radioactivity was determined in a T-spectrometer. Total 
binding (6-10%) was determined in the absence of unlabelled 
peptide and nonspecific binding (2.5-3.5%) by the addition 
of 10- 6 M or 10··· 7 M GnRH. agonist or antagonist. 
GnRH agonist 1 was labelled with Nai. =-~~ 1 (Kerdelhue et 
al., 1973) and purified by QAE Sephadex A-25 chromatography 
(Nett and Adams. 1977). The specific activity. as determined 
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by self-displacement in the rat pituitary receptor assay, 
was 959-1066 ~Ci/~g. The proportion of [ 1 2 ~ I]GnRH agonist 1 
bound by excess pituitary membranes (35-40%) was taken into 
account in the Scatchard analysis of data. Elbo (effective 
dose required to displace 50% of the labelled agonist) 
values were determined using an Allfit program of DeLean et 
al. (1978). Kds (dissociation constants) were estimated from 
Scatchard analysis and from ED~o s using the formular of 
Cheng and Prusoff (1973). The binding studies were performed 
with pools of membranes from two to three pituitaries, and 
each study included a displacement curve of the GnRH agonist 
1 as a reference point for determining relative potencies. 
These findings were then confirmed by examining binding of 
all the analogs in a single study. 
The validity of the GnRH binding assay using partially 
purified membranes was previously established by comparison 
of the relative potencies of a range of GnRH analogues in 
binding to membranes and dispersed pituitary cells in the 
rat (Loumaye et al., 1982). Similarly, dispersed human 
pituitary cells specifically bound [1 2 ~I]GnRH agonist (data 
not shown). High performance liquid chromatography analysis 
of GnRH, GnRH analogues and [1 2 ~I]GnRH agonist revealed no 
measurable breakdown of the peptides , when incubated with the 
pituitary membranes under the receptor assay conditions (150 
min at 4°C). GnRH was partially degraded (about 20%) by 
membranes when incubated at 37° C. 
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Studies on the effects of cations on [ 12~ I)GnRH agonist 
1 binding were carried out as described above, with the 
exception that EDTA was omitted from the assay buffer and 
various concentrations of CaCl 2 , MgCl 2 , NaCl and KCl were 
included. Ionic concentrations were confirmed by atomic 
absorption spectrometry. The amount of Ca2 + bound by BSA in 
the assay buffer was calculated to be less than 3% . Specific 
binding in the presence of the monovalent and divalent 
cations was compared with control tubes lacking these ions. 
The effect of pH on [12~ I)GnRH agonist 1 binding to 
human and rat pituitary membranes was also investigated 
using 10 mM HEPES 
BSA as the assay 
containing 1 mM EDTA, 1 mM DTT and 0.1% 
buffer for pH 6.0 to 7.5 and buffer A 
(described above) for pH 7.5 to 8.5. 
Ligand-immunoblotting 
technique for receptor 
~isualisation 
The procedure was as previously described (Eidne et 
al., 1985). Membranes were prepared from human and rat 
pituitaries in 20 mM Tris HCl, 0.15 M NaCl , 1 mM CaCl2, 1 mM 
phenylmethane-sulfonyl fluoride, pH 8.0 and solubilised in 
125 mM Tris maleate, 160 mM NaCl, 40 mM e~D-
octylglucopyranoside, pH 6.0, at 4°C for 10 min. The 
solubilised membranes were immediately electrophoresed at 
4°c on a 0.1% sodium dodecyl sulphate, polyacrylamide 6-12% 
linear gradient gel (Laemmli, 1970) at 25 mA for 45 min and 
then at 35 mA for 60 min. The electrophoresed proteins were 
Western-blotted onto nitrocellulose (Bio-Rad Laboratories, 
Richmond, CA) in 50 mM Tris, 200 mM glycine, and 20% 
(vol/vol) ethanol at 195 mA for 2 h at 23-25°C. Protein 
molecular weight markers (Pharmacia Fine Chemicals, Uppsala, 
Sweden) transferred onto the nitrocellulose were stained 
with Amido black. Nitrocellulose strips with separated 
membrane proteins were incubated with buffer C (50 mM Tris 
HCl, 90 mM NaCl, 50 mg/ml BSA, fatty acid free (Miles 
Laboratories, Inc.,· Elkhart, IN) pH 8.0) at 23-25°C for 1 h. 
They were then incubated with buffer C containing 10-b M 
GnRH for 45 min and washed several times with 50 mM Tris 
HCl, 90 mM NaCl, 5 mg/ml BSA, pH 8.0. The strips were 
incubated for a further 30 min in 10 ml buffer C containing 
200 ul antiserum 1076, which is directed towards the middle 
region of GnRH (King and Millar, 1982), or non-immune serum 
followed by a series of washes and then a 30 min incubation 
with horseradish peroxidase-conjugated sheep antirabbit 
immunoglobulin G (N.L.Cappel Laboratories, Cochranville, PA) 
at a concentration of 50 ul in 25 ml buffer C. The strips 
were washed and the GnRH receptors visualised by incubating 
with 4-chloro-1-naphthol (Sigma Chemical Co., St. Louis, MO) 
(0.5 mg/ml in 50 mM Tris HCl, 150 mM NaCl, pH 8.0 and 
40 
0.0003% Ik02) for 5 min. The reaction was terminated by 
several washes in distilled water. 
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RESULTS 
Affinity and specificity of 
the h~man GnRH receptor 
Membranes prepared from human anterior pituitaries 
removed at autopsy bound [ 1 25 l]GnRH agonist 1 with high 
affinity and specificity (Fig. 2.lA). Scatchard analysis 
indicated that the binding was saturable and involved a 
single class of high affinity sites. The Kd of the human 
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Fig. 2.1 Displacement of (12~1]-GnRH agonist binding to human (A) and rat (B) pituitary membranes by unlabelled GnRH (0) , GnRH agonist ( •) , GnRH antagonist 1 ( o ) , GnRH antagonist 2 <•> , GnRH 1-5 (A), (D-Ala1 )-somatostatin (V), and TRH (~). Inserts show Scatchard analysis of the binding of GnRH agonist. 
TABLE 2.1. Apparent dissociation constants of GnRH, agonist 1 and antagonists 1 and 2 binding to human and rat pituitary membranes 
GnRH 
GnRH agonist 1 
GnRH antagonist 1 








0. 32.±.0. 14 
0 . 32.±.0 . 26 

















2. 04_±0. 85 
0. 20.±0 .10 
0.66±.0.46 
0.06±0.01 
All values represent mean± SEM of binding studies carried out in triplicate using pooled membranes from 3 cadavers or 12 rats. ~s were calculated by Scatchard analysis for GnRH agonist 1 and by the method of Cheng and Prusoff (1973) for GnRH and GnRH antagonists 1 and 2. Binding studies were carried out on three different pools of pituitary homogenates. The mean~ values for the human GnRH receptor in the three pituitary homogenate pools ranged from 2.8-9.0nM for GnRH, 0.11-0.40nM for GnRH agonist 1, 0.14-0.32nM for GnRH antagonist 1, and 2.8-4.6nM for GnRH antagonist 2. 
*Significantly different from ~ for rat pituitary (p<0.005) as determined by the unpaired Student's t test. 
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pituitary receptor, calculated from the ED~o (Cheng and 
Prusoff, 1973), was 4.81 nM, which was similar to that of 
the rat receptor (4.71 nM) as determined in paral l el studies 
(Fig. 2.1; Table 2.1). GnRH agonist 1 and GnRH antagonist 1 
had higher affinities for the human receptor (Kc.s of 0.32 
nM) than GnRH, and these values were similar to t hose of the 
rat (Fig. 2.1 ; Table 2.1). GnRH antagonist 2 , h owever , bound 
the human GnRH receptor with a much lower affinity than the 
rat receptor (Kc.s of 4.21 nM and 0.09 nM respectively). 
There was no difference in the binding of GnRH, agonist 
1 and both antagonists 1 and 2 to freshly prepared rat 
pituitary membranes and membranes prepared 48 h post-mortem 
(Table 2.1), which was the maximum period that human 
material was obtained post-mortem. Rat pituitary GnRH 
receptor number was unchanged 24 h post-mortem (Table 2.2). 
At 48 h post-mortem, receptor number was significantly 
diminished and by 96 h it was 25% that of the fresh 
material. 
A further five GnRH analogues were tested in the human 
and rat GnRH receptor binding assays, of which three were 
shown to have significantly lower affinities for the human 
receptor than the rat receptor (Table 2.3). 
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TABLE 2.2. GnRH receptor number of rat pituitary membranes prepared at various times post-mortem 
Time post-mortem GnRH agonist bound 
(h) (fmol/pituitary) 
0 217 ±. 5 
24 247 ±. 17 
48 148 ±. 2* 
96 53 ± 9* 
All values represent mean ± SEM of studies performed in triplicate using pooled membranes prepared from 3 rats . 
* Significantly different from receptor number of freshly prepared rat pituitary membranes (p<0.001) as determined by the unpaired Student's t test. 





GnRH 4.90 ± 0.81 4.14 ± 0.22 
Chick GnRH II 95.3 ± 4.7* 28.7 + 2.4 
GnRH agonist 2 5 . 50 ± 0.60* 0.59 ± 0.16 
GnRH agonist 3 6.60 ± 2.0 2.04 + 0.22 
GnRH agonist 4 9.89 ± 5.91 3.16 ± 0.35 
GnRH antagonist 3 11.4 ± 2.3** 1. 00 + 0.20 
All values represent mean± SEM of binding studies carried out in duplicate or triplicate using pooled membranes from 3 cadavers or 16 rats. 
* Significantly different from l<ci for rat pituitary (p<0.01) as determined by the unpaired Student's t test. 
** Significantly different from l<ci for rat pituitary (p<0.05) as determined by the unpaired Student's t test. 
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The effect of cations on human 
and rat GnRH receptor binding 
In the presence of 0.6 mM Mg2 + [ 12~ I]GnRH agonist 1 
binding to the human receptor was reduced to a greater 
degree than occurred with the rat receptor (Fig. 2 . 2A) . This 
differential effect of Mg2 ~ · was even more pronounced at 6 . 0 
mM. A greater degree of inhibition of binding to the human 
receptor also occurred in the presence of 1.0 and 4.0 mM 
Ca2 +. The presence of 10 mM Na+ or 100 mM K+ also resulted 
in inhibition of [ 1 2 ~ I]GnRH agonist 1 binding, which was 
significantly greater in the human than in the rat (Fig. 
2.2B). At more physiological concentrations (100 mM Na2 + and 
10 mM K+), however, the inhibition of binding due to the 








The concentration of H+ had a similar effect on 
receptor binding in the human to that in the rat (Fig . 2.3); 
the optimum pH for binding being between 7.0 and 7.5 for 
both species. 
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Fig. 2.2 The effect of divalent (A) and monovalent (B) cations on [1 2 ~ 11-GnRH agonist binding to human and rat pituitary membranes, expressed as per cent of specific binding in the absence of ions. 
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8.0 9.0 
Fig. 2.3 The effect of pH on [ 1 ~~ 11-GnRH agonist binding to human (broken line) and rat (solid line) pituitary membranes. HEPES buffer was used for pH 6.0 to 7.5 and Tris buffer for pH 7.5 to 8.5. 
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Dete~mination of the molecular 
size of human and rat GnRH 
receptors 
The molecular sizes of the human and rat GnRH receptors 
were studied using a ligand-immunoblotting technique (Eidne 
et al., 1985). A single GnRH binding protein was present in 
human pituitary membranes which was consistently (as 
determined on 11 separate occasions) of higher molecular 
weight than that of the rat (Fig. 2.4A). The molecular 
weights, determined from a plot of log-molecular weight of 
molecular weight markers vs. relative migration, were 64,000 
daltons for the human receptor and 60,000 daltons for the 
rat receptor. The receptor bands were not visible when the 
nitrocellulose strips were incubated with non-immune rabbit 
serum (Fig. 2.4B) or with GnRH antisera requiring those 


















Fig . 2 . 4 Electrophoretic separation and ligand-immunoblotting visualisation of human (lanes 2 and 4) and rat (lanes 1 and 3) pituitary GnRH receptors using (A), antiserum 1076, which is directed towards the middle region of GnRH (King and Millar, 1982); and (B), non-immune serum. 
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DISCUSSION 
The human GnRH receptor has been shown to bind GnRH 
with a high affinity and specificity which was similar to 
what has been observed in the rat in this and previous 
studies (Clayton and Catt, 1980; Clayton and Catt, 1981; 
Millar et al., 1982a; Perrin et al., 1980b) . While the human 
receptor also bound GnRH agonist 1 and GnRH antagonist 1 
with similar affinities to the rat receptor, it differed 
from the rat in its binding of GnRH antagonist 2, indicating 
a possible species difference. Human and rat ovarian GnRH 
receptors have also been found to differ in their affinity 
for GnRH analogues (Pieper et al., 1981; Popkin et al., 
1983) . 
To ensure that this difference in the binding 
affinities of the human and rat GnRH receptors for GnRH 
antagonist 2 was not due to post-mortem changes in the human 
receptor, pituitary membranes prepared from groups of three 
rats kept under similar conditions to those in the mortuary 
were compared with fresh' material. There was no difference 
in the binding of any of the GnRH analogues to freshly 
prepared rat pituitary membranes and membranes prepared 48 h 
post-mortem. 
In the light of these findings, a further five GnRH 
analogues were selected, by virtue of their relatively poor 
51 
binding affinities for the sheep GnRH receptor, and tested 
in the human receptor binding assay. Three of the analogues 
tested, namely GnRH agonist 2, GnRH antagonist 3 and chicken 
GnRH II, bound the human GnRH receptor with significantly 
lower affinities than they bound the rat receptor, thus 
further substantiating the contention that there is a 
species difference between the two receptors. In order to 
fully characterise the ligand binding requirements of the 
human GnRH receptor, the binding affinities of several more 
analogues, with different hydropathic and steric properties, 
need to be investigated. 
The human GnRH receptor also exhibited differences from 
the rat receptor in the inhibitory effects of cations on 
[ 1 2 ~ I]GnRH agonist 1 binding. The divalent cations caused a 
significantly greater inhibition of binding to the GnRH 
receptor in the human than in the rat. Differences in the 
effects of monovalent cations on binding in the human and 
the rat were not as marked as the binding differences in the 
presence of the divalent cations. Diminished binding to the 
rat GnRH receptor in the presence of various cations has 
been previously described (Marian and Conn, 1980), and 
reported to be due to a decrease in receptor affinity rather 
than receptor number. In view of the scarcity of human 
material it was not possible to determine whether the 
decreased binding to human pituitary membranes was due to 
changes in receptor number or affinity. 
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In spite of these cationic differences, the 
concentration of H+ had a similar effect on receptor binding 
in the human to that in the rat: the optimum pH for binding 
being between 7.0 and 7.5 for both species. 
The apparent difference in rat and human pituitary 
receptor binding characteristics may be due to molecular 
differences in the receptors which affect charge, 
conformation and hydrophobicity. The molecular sizes of the 
rat and human receptors were therefore studied using a 
ligand-immunoblotting technique (Eidne et al., 1985). The 
molecular weights were 64,000 daltons for the human receptor 
and 60,000 daltons for the rat receptor. The latter 
estimation is in agreement with a previous report (Hazum, 
1981b). These receptor bands may represent only the binding 
component of a receptor protein complex, as a recent study 
using target size analysis of the rat pituitary GnRH 
receptor gave a molecular size of 136,346 daltons (Conn and 
Venter, 1985). This is approximately twice that in our 
studies, which were carried out under denaturing conditions. 
The GnRH binding protein bands were specific by a number of 
criteria. They were not visible when the nitrocellulose 
strips were incubated with non-immune rabbit serum or with 
GnRH antisera requiring those regions of GnRH which bind the 
receptor.The differences in apparent molecular size between 
the human and rat GnRH binding proteins may be due to 
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differences in glycosylation or amino acid composition of 
the processed receptor proteins. It is unlikely that these 
changes are due to the presence of different degradative 
enzymes in the respective tissues since the membranes were 
prepared in the presence of phenylmethane-sulfonyl fluoride, 
a potent serine protease inhibitor. A more detailed study 
would be required to determine the relevance of this 
molecular size difference with regard to the binding 
characteristics of the human and rat GnRH receptors. 
These studies have established that the human pituitary 
contains a single class of high affinity specific binding 
sites for GnRH. A previous study reported low binding of 
[
1 2 ~ IJGnRH analogue to human pituitary membranes (Clayton 
and Huhtaniemi, 1982), but the nature of the binding sites 
was not established. In this study, the pituitaries obtained 
at autopsy from premenopausal women had high specific 
binding (3.1-6.7% of total [1 2 ~ I]GnRH analogue) comparable 
to that found in the rat, whereas the male pituitaries had 
lower binding (0.7-1.0% of total [12~I]GnRH analogue) (data 
not shown). No other differences in binding related to 
cause, or time after death were found. 
The present investigation has demonstrated the 
feasibility of using human pituitaries obtained post-mortem 
for characterising GnRH binding sites. It is clear that 




its affinity for GnRH and certain analogues, it 
the rat receptor in its interaction with at 
least four GnRH analogues, its ionic requirements for 
monovalent and divalent cations, and the molecular size of 
the GnRH binding protein. 
Detailed characterisation of the specificity of the 
human pituitary GnRH receptor may provide data of value in 
predicting which GnRH analogues are appropriate for clinical 
application, thereby possibly reducing the number of 
clinical investigations employed in the selection of 
potentially useful GnRH analogues. 
CHAPTER3 
CULTURE OF FUNCTIONALLY ACTIVE HUMAN 




In vivo studies on hypothalamic peptide regulation of 
pituitary hormone secretion in man are complicated by the 
simultaneous interaction of various modulators such as 
neurotransmitters, steroids and other hormones (Pohl and 
Knobil, 1982; Sandow, 1983; Chappel, 1985; Kalra, 1985; 
Kalra and Kalra, 1985; Plant, 1986). In vitro studies using 
cultured pituitary cells are therefore advantageous in that 
the direct effect of individual hormones, hormone analogs 
and neurotransmitters may be investigated. To date, such 
studies have been restricted to laboratory and domestic 
animals. The lack of culture systems for normal human 
pituitary cells and the resultant dearth of information on 
the mechanisms of pituitary hormone regulation in vitro 
encouraged us to explore the possibility of culturing 
functionally viable human pituitary cells from post mortem 
tissue. This chapter describes methodology for the culture 
of human pituitary cells which respond to all of the 
hypothalamic releasing hormones, and the results of studies 
of the mechanisms and kinetics of gonadotropin secretion and 
the relative potencies of GnRH analogs. 
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MATERIALS AND METHODS 
Hormones 
GnRH, chicken GnRH II, (His~.Trp 7 ,Tyr8)-GnRH. GnRH 
agonist 1, (D-Ala0 , N~MeLeu7 , Pro9 NEt)-GnRH. GnRH agonist 
2. (D-Trp~.Trp 7 )-GnRH. GnRH agonist 3, (Trp7 )-GnRH. and GnRH 
agonist 4. (His~)-GnRH. were synthesized by Dr R C deL 
Milton. University of Cape Town Medical School (Cape Town, 
South Africa): GnRH antagonist 1, (Ac-D-Nal(2) 1 .D-a-Me-4-
ClPhe2,D-3-Pal3,D-Ar~.D-Ala10Ntk)-GnRH. was supplied by Dr 
R Roeske. Indiana University School of Medicine 
(Indianapolis. IN); GnRH antagonist 2. (D-pGlu1 ,D-Phe2 ,D-
Trp3•0)-GnRH. was supplied by Dr J E Rivier. The Salk 
Institute (San Diego, CA); and GnRH antagonist 3, (Ac-D-
Nal(2)1, D-a-Me-4-ClPhe2 ,D-Trp3 ,D-Arg6,D-Ala10 Ntk)-GnRH, by 
Dr R Roeske. Synthetic TRH was obtained from Beckman 
Instruments Inc. (Palo Alto, CA); GHRH(l-29)Nl-k from Dr DH 
Coy, Tulane University (New Orleans. LA): and ovine CRH was 
from Dr N Ling, The Salk Institute (San Diego, CA). 
Preparation of ce11s 
Human anterior pituitary glands were obtained at 
autopsy from 33 men. 20 to 40 years old, within 24 h after 
accidental death. The glands were placed into ice cold 
sterile HEPES buffer (137 mM NaCl. 5 mM KCl. 0.7 mM Na2HP04, 
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10 mM glucose, 360 uM CaCl2, 1% (w/v) 







7.2). After removal of the capsule, the tissue was diced and 
incubated in HEPES buffer containing 0.9% collagenase (142 
U/mg, CLS II Worthington Biochemicals, Freehold, NJ) and 1.8 
mg% DNAase 
37°C for 
(Miles Biochemicals, Eppindust, South Africa) at 
1 h (Vale et al., 1972). The cells were harvested 
by centrifugation at 450 x g for 7 min and washed twice with 
HEPES buffer before final suspension in minimal essential 
medium (MEM with Hank's salts, Gibco, Paisley, Scotland) 
containing 10% foetal calf serum, 0.1 mM glutamine and 100 
U/ml penicillin (Glaxo (Pty) Ltd., Wadeville, RS A), 100 
mg/ml streptomycin (Novo Industries, Johannesburg, R SA) 
and 100 mg/1 neomycin (Upjohn (Pty) Ltd., Isando, RS A). 
Cells obtained from between 1 and 6 pituitary glands were 
pooled and distributed into tissue culture dishes (Falcon t 
3046 6-well multidish) such that the dishes contained 
approximately 10~ dispersed cells per well (4 ml medium). 
The dishes were incubated at 37°C, 95% humidity and 5% C°-2. 
Cells sufficient for 6 wells were usually obtained from one 
pituitary. 
Rat anterior pituitary glands were obtained from adult 
male Long-Evans rats (350-450g) within minutes of death by 
decapitation and were processed as described above. Cells 
sufficient for 3 wells usually were obtained from one rat 
pituitary. 
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Incubation of cells 
After 3 to 4 days in culture, the cells were washed 5 
times with MEM, and test substances added to duplicate or 
triplicate wells. After 3 hours of incubation the medium was 
removed and added to tubes containing BSA, to prevent 
absorption of gonadotropins , such that the final 
concentration of BSA in the samples was 0.1%. They were then 
centrifuged at 400 x g and the supernatants removed and 
stored at -20°C until assay for LH and FSH, and in the TRH , 
GHRH and CRH studies for TSH, prolactin, GH and ACTH. 
To study the kinetics of gonadotropin secretion during 
a 1 h continuous incubation with 100 nM GnRH, the cells were 
incubated with GnRH for 5 min following which the medium was 
removed and replaced with fresh medium containing GnRH. This 
step was repeated at 5 min intervals for the first 20 min, 
and at 10 min intervals for the following 40 min. At the end 
of 60 min the cells were stimulated with 1 uM A23187 for 5 
min. 
To investigate GnRH desensitization, the cells were 
incubated with increasing doses of GnRH for 2 hours and the 
medium then was removed. Fresh medium containing the same 
doses of GnRH was added and the cells incubated for a 
further 2 hours. The medium was again removed. At the end of 
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the 4 h incubation period the cells in each well were lysed 
with 1 ml 1% Triton X-100 in water for 1 hour at room 
temperature and 
immunoreactivity. 
the lysate analysed for LH and FSH 
Each experiment was repeated with similar results on at 
least 2 occasions. Each table and figure shows the results 
of a single experiment performed on a single batch of 
cultured cells, unless stated otherwise. 
Radioimmunoassays 
All samples from an individual experiment were analysed 
at the same time in each assay and all assays were performed 
in duplicate. Human LH and FSH were measured by RIA using 
reagents supplied by the National Hormone and Pituitary 
Program, Baltimore MD. The intraassay CVs for these assays 
were 2.9 and 4.9 % respectively. Rat LH also was measured by 
RIA using NHP reagents (intraassay CV 5.9 %) . TSH was 
measured by RIA using kits obtained from Amersham, 
Radiochemical Centre, United Kingdom: PRL and GH by RIA 
using kits obtained from Serono, Woking, United Kingdom; and 
ACTH by RIA using kits obtained from CIS, Gif-sur-Yvette, 
France. The intraassay CVs for TSH, PRL, GH and ACTH were 
4.5, 6.2, 13 . 5 and 6 . 2 % respectively. 
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Immunocytochemistry 
The cultured human pituitary cells were fixed in 
methanol for 5 min, washed twice with PBS (0.01 M Na2HP04, 
0.15 M NaCl, pH 7.6) and drained. The cells then were 
covered with porcine serum diluted 1:20 in PBS for 10 min 
and drained. Test cells were incubated with rabbit anti-LH 
serum or rabbit anti-FSH serum (Dako Corp, Denmark) diluted 
1:200 in PBS for 30 min at room temperature, control cells 
were incubated with porcine serum alone. The cells then were 
washed with PBS for 30 min, drained and incubated with 
porcine antirabbit IgG (Dako Corp) diluted 1:20 in PBS for 
30 min at room temperature. The cells were drained, washed 
with PBS for a further 30 min and incubated with horseradish 
peroxidase/rabbit-antihorseradish peroxidase (Dako) diluted 
1:20 in PBS for 30 min. After washing with PBS for a further 
30 min, the gonadotropes were visualised by incubation for 
approximately 5 min with 3,31-diaminobenzidine 
tetrahydrochloride (Sigma Chemical Co., St Louis, MO) (0.5 
g/1 in PBS, and 1% lb02). The reaction was terminated by 
several PBS washes. The cells were counterstained with 
hematoxYlin for 5 min after which they were washed in water, 
dehydrated in graded ethanol (70 to 100%), cleared in xylol 




The data points shown in the figures and text are the 
mean± SEM of results from triplicate wells of a single 
experiment assayed in duplicate. Intra-experiment 
statistical significances were 
variance or unpaired Student's 
evaluated by analysis of 
t test. E~o (concentration 
of agonist required to stimulate 50% of maximum gonadotropin 
release) and 
inhibit 50% 
IC.So (concentration of antagonist required to 
of GnRH-stimulated gonadotropin release) values 
were determined using an Allfit dose-response analysis 
program modified from the Allfit program of De Lean et al. 
( 1978) . 
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RESULTS 
Sixty four percent of the human pituitary cultures were 
successful. in that some cell attachment occurred within 2 
days after initiation of the culture. Cell viability prior 
to culture, as assessed by trypan blue exclusion, ranged 
from 40-50%, while after 3-4 days in culture the viability 
of the attached cells was in excess of 95% as non-viable 
cells did not attach. Immuno-peroxidase staining of the 
A . . 
Fig. 3.1 Immunocytochemical staining of the cultured human 
pituitary cells. Experimental cells were immuno-peroxidase 
stained using a hLH antiserum and counterstained with 
hemotoXYlin (A). Positively stained cells or cell clusters 
are indicated by the arrows. Of the total pituitary cell 
population 15.2 ± 2.4 % contained LH. Control cells (B) were 
incubated with non-immune serum and showed no positive 
staining. 
6 -::-. .., 
cultured pituitary cells revealed that, as in the rat 
(Childs et al., 1983), 15.2 ± 2.4% (mean± SEM, n=5) of the 
cells contained LH (Fig. 3.lA) and 12.3 .±. 1.1% (n=5) of the 
cells contained FSH. Double staining to determine the 
percentage of bihormonal cells was not done. Control cells , 
which were incubated with non-immune serum, showed no 
positive staining (Fig. 3. lB). 
Effect of the hypothalamic 
releasing hormones on hormone 
secretion from cultured human 
pituitary cells 
GnRH, TRH, GHRH and CRH significantly stimulated 
release of LH and FSH, TSH and PRL, GH and ACTH, 
respectively (Table 3 .1) . There was an additional 




TABLE 3.1. Effects of hypothalamic releasing hormones , on pituitary hormone 
























































156. 3±12. 1 * 
All values represent mean± SEM of triplicate 3 h incubations using 
pooled cells from 3 cadavers. 
* Significantly different from basal release (p<0.01), as determined 
by analysis of variance. 
+ Significantly different from TRH-stimulated TSH release (p(O. 01), as 
determined by analysis of variance. 
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The biological potencies of 
GnRH and GnRH analogues in 
cultured human and rat 
pituitary cells 
GnRH stimulated LH release from cultured human 
pituitary cells in a dose-dependent manner. the EC~a being 
0.95 nM (Fig. 3.2A; Table 3.2). Its potency in rat pituitary 
cells was similar (E~o 2.0 nM) (Fig. 3.2B; Table 3.2). GnRH 
agonists 1 and 2. and chicken GnRH II were as active in 
stimulating GnRH release from cultured human pituitary cells 
(EC~os of 0.08 nM. 0.53 nM and 16.8 nM respectively) (Fig. 
3.3A; Table 3.2) as from rat pituitary cells (EC~c,s of 0.35 
nM. 0.80 nM and 30.0 nM respectively) (Table 3.2). GnRH 
agonist 3 was marginally more active in the human (EC:,o of 
0.22 nM) (Fig. 3.3 A; Table 3.2) than in the rat (EC~c, of 
1.30 nM) (Table 3.2), while GnRH agonist 4 was more than 10-
fold more active in the human (EC:,o(human) of 0.57 nM; 
EC~o(rat) of 8.20 nM) (Fig. 3.3 A; Table 3.2). GnRH 
antagonists 1, 2 and 3 were less active in inhibiting GnRH-
stimulated gonadotropin re'lease from human pituitary cells 
(IC~os of 2.60 nM, 72.0 nM and 23.6 nM respectively) (Fig. 
3.3 B; Table 3.2) than from rat pituitaries (IC~os of 0.52 
nM, 18.7 nM and 0.47 nM respectively) (Table 3.2), with the 
most pronounced difference being exhibited by GnRH 
antagonist 3 which was 50-fold less active in the human than 
in the rat. The biological potencies of all the analogues 
66 
tested for stimulating or inhibiting FSH release from the 
cultured human pituitary cells were similar to those for LH 
release (Table 3.2). 
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Fig. 3.2 Effect of increasing doses of GnRH on LH secretion from human (A) and rat CB) pituitary cells. All values represent mean ± SEM of triplicate 3 h incubations using pooled pituitary tissue from 3 cadavers or 10 rats. The EC.So for GnRH-st imu 1 ated LH re l'ease was 1. 25 nM for human and 2.45 nM for rat cells. 
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Fig. 3.3 A. Effect of increasing doses of GnRH (e), chicken 
II GnRH (~), GnRH agonist 1 (0), GnRH agonist 2 (A), GnRH 
agonist 3 <•> and GnRH agonist 4 (D) on LH secretion from cultured human pituitary cells. B. Effect of increasing doses of GnRH antagonist 1 <*), GnRH antagonist 2 <*> and GnRH antagonist 3 ( x) on 3nM GnRH-stimulated LH secretion from cultured human pituitary cells. 
All values represent the mean of triplicate 3 h incubations using pooled pituitary tissue from 2 to 5 cadavers, and are expressed as percent of maximum release in the case of the agonists, and as percent of 3nM GnRH-stimulated LH release in the case of the antagonists. Basal release was subtracted from stimulated values in each case. Each dose response curve is the result of an individual experiment. 
68 
TABLE 3.2 . Gonadotropin releasing or release- inhibiting 
activity of GnRH and several GnRH analogues in the human and 
the rat. 
LH release FSH release 
EC~o human EC~· ... -. rat EC-; ..., human 
( nMl ( nM) ( nM) 
GnRH 0.95 + 0.25 2 . 00 + 0.28 0.72 + 0.16 
Chick I I GnRH 16.8 + 8.2 30.0 + 0.50 17.5 + 3.50 
Agonist 1 0.08 + 0.02 0.35 + 0.04 0.07 + 0.03 
Agonist 2 0.53 + 0.10 0.80 .±. 0.06 0.92 + 0.38 
Agonist 3 0.22 + 0.03 1.30 + 0 . 30* 0 . 36 + 0.11 
Agonist 4 0.57 + 0.17 8 . 20 .±. 0.19** 0.40 .± 0.15 
LH inhibition FSH inhibition 
I C~·;o human I C.,..;o rat I c ~i; (-, human 
(nMl (nM) (nM) 
Antagonist 1 2.60 + 0.10 0 .52 + 0. 12** 3.10 .:I: 1.50 
Antagonist 2 7 2 .0 + 8.0 18.7 + 11.3* 82 . 0 ± 18.0 
Antagonist 3 23.6 + 1. 6 0.47 + 0.07** 25.3 + 3.8 
All values represent mean ± SEM of EC~o s or IC~o s 
obtained from 2 separate 3 h experiments which were carried 
out in triplicate using cells from 13 cadavers or 20 rats. 
* Significantly different from El)...., o for human pituitary 
cells (p ( O.l) as determined by the unpaired Student's t 
test. 
** Significantlv different from E~~. for human pituitary 
cells (p(0 . 01) as determined by the unpaired Student's t 
test. 
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THe kinetics of LH and FSH 
secretion in response to 
stim~lation ~ith 100 nM GnRH 
Stimulation of the cells with 100 nM GnRH for 60 
minutes resulted in a biphasic release of LH (Fig. 3.4A) and 
FSH (Fig. 3.4B}. The initial release phase was rapid, 
occurring during the first 3 to 4 minutes, while the plateau 
phase was more protracted; continuing for the ensuing 40 
minutes. Stimulation with the Ca2 • -ionophore, A23187, at the 
end of the 60 min of GnRH stimulation elicited additional LH 
and FSH release but the response to the ionophore was 
significantly less than that in those cells which had not 
been stimulated with GnRH . Thus, GnRH stimulation leads to 
partial desensitization of the gonadotropes. The kinetics of 
both LH and FSH release were similar, so that the ratio of 
LH to FSH release was constant during both secretory phases 
( F i g . 3 . 4C} . 
ca=- and protein kinase C 1n 
gonadotropin secretion 
GnRH-stimulated LH and FSH secretion from cultured 
human pituitary cells was Ca2 •-dependent. In the presence of 
3 mM EGTA the gonadotropin response to GnRH was abolished 
(Fig. 3.5A}. EGTA had no effect on LH and FSH release in the 
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Fig. 3.4 Effect of GnRH (100 nM) stimulation on LH (A) and FSH (B) secretion from cultured human pituitary cells as a function of time. The cells were incubated with 100 nM GnRH from 0-60 min and then with 1 uM A23187. GnRH-stimulated gonadotropin secretion is represented by the solid circles and line and basal secretion by the open circles and broken line. 
All values are mean ± SEM 
cells from 2 cadavers. 
All GnRH-stimulated values 
the unstimulated (p< 0.01). 
remained constant. The 
significantly less (p(0.01) 
unstimulated cells. 
of triplicate incubations using 
were significantly higher than 
The ratio of LH/FSH released (C) 
A23187-stimulated value was 
in GnRH-stimulated cells than in 
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Fig. 3.5 Effect of 3 mM EGTA (A). 1 uM A23187 (B) and 50 nM 
TPA (C) on GnRH-stimulated LH and FSH secretion from 
cultured human pituitary cells. 
All values represent mean ± SEM of triplicate 3 h 
incubations using cells from 9 cadavers. 
Significantly different from basal * p<0.01, ** p(0.05 as 
determined by analysis of variance. 
1 ng/ml LH is equivalent to 0.277 IU/1 and 1 ng/ml FSH is 
equivalent to 0.053 IU/1. 
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TABLE 3.3 Effect of TPA and dbcAMP on [3 HJ-leucine 






3 H]-leucine (% basal) 
100.0 ± 0.24 
92.5 + 0.19 
101.0 ± 0.17 
All values represent mean± SEM of duplicate 3 h 
incubations using pooled cells from 6 cadavers. 
absence of GnRH. The Ca2 +-ionophore, A23187, caused 
significant LH and FSH release at a dose of 1 uM (Fig. 
3.5B). The phorbol ester, TPA, at a dose of 50 nM also 
stimulated LH and FSH release suggesting that phospholipid 
turnover and protein kinase C may play a role in GnRH-
stimulated gonadotropin release (Fig. 3.5C). This effect of 
TPA was unlikely to be due to a non-specific toxic effect of 
the phorbol ester on the cells since incorporation of [3 H]-
leucine into protein was unaffected (Table 3.3). 
The role of cAMP in 
gonadotropin secretion 
Dibutyryl cAMP (dbcAMP) caused a dose-dependent 
increase in LH and FSH secretion from cultured human 
pituitary cells (Table 3.4). The stimulatory effect of the 
cyclic nucleotide was not secondary to a toxic effect on the 
cells since incorporation of [3 H]-leucine into protein was 
not altered by cAMP at these doses (Table 3.3). 
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TABLE 3.4 Effect of dbcAMP on LH and FSH secretion from 
cultured human pituitary cells 
LH release FSH release 
(ug/ml} Cug/ml) 
Basal 1.88 + 0.24 0.60 + 0.11 
10--·<!<• M GnRH 8.56· + 0 .68* 2.94 .:+'. 0.36* 
O.lmM dbcAMP 3.24 :t 0.19** 1. 70 ± 0 .10* 
1.0mM dbcAMP 6.20 + 0. 20* 2.74 t 0 .18* 
All · values represent meant. SEM of triplicate 3 h 
incubations using pooled cells from 4 cadavers. 
Significantly different from basal values* p<0.01. 
** p<0.05 .- as determined by analysis of variance. 
Desensitisation of h-u.man 
pit-u.itar~ ce1ls to subsequent 
stim-u.lation ~ith GnRH 
GnRH-st"imulated gonadotropes became desensitized to 
subsequent stimulations with GnRH. Followinq an initial 2 
hour incubation with GnRH ir1 doses ranging from 0.1 to 100 
nM. the LH released during a second 2 hour incubation with 
GhRH in the same dose was reduced by 50-100% (Fig. 3.6A). 
The inhibition of FSH release ranged from 63-92% (Fig. 
3.6B). The total LH and FSH cell content declined to 52% 
(Fig. 3.6A: Fig. 3.7A) and 51% (Fig. 3.6B: Fig. 3.7B) 
respectively. after 100 nM GnRH stimulation. When the 
initial incubation with GnRH was carried out under Ca2 +-free 
conditions. the cells still became desensitised to a further 
stimulation with GnRH <Fig. 3.7 A and B). The degree of 
-- --.1st stimulation Q) B Q) 
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Fig. 3.6 The effect of two 2 h incubations with increasing doses of GnRH on LH (A) and FSH (B) secretion from cultured human pituitary cells. An initial 2 hour incubation with 0.01 to 100 nM GnRH (solid line) was followed by a second incubation (broken line) after which the cells were lysed and LH and FSH cell content measured (0). 
All values represent mean ± SEM of triplicate incubations using cells from 3 cadavers. 
Significantly different from initial 2h incubation* p<0.01. ** p<0.05 as determined by analysis of variance. 1 ug/well LH is equivalent to 0.277 IU/well and 1 ug/well FSH is equivalent to 0.053 IU/well. 
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Fig. 3.7 Effect of an initial 2 h incubation with l0- 0 M 
GnRH. in the presence or absence of Ca2 +, or 10-0 M GnRH antagonist 2. followed by a second 2 h incubation with 10- 6 M GnRH, on LH (A) and FSH (B) secretion from cultured human pituitary cells. Incubation I is represented by the stippled bars, incubation II by the hatched bars and cellular LH and FSH content, at the end of the experiments, by the open bars. 
All values represent mean ± SEM of triplicate incubations using pooled pituitary tissue from 3 cadavers. 
Significantly different from gonadotropin release in response to 10- 0 M GnRH from previously untreated cells; * p(0.001, ** p(0.01. 
Significantly different from gonadotropin release in response to a second 2 h stimulation with l0- 6 M GnRH; + p(0.001 
1 ug/ml LH is equivalent to 277 IU/1 and 1 ug/ml FSH is equivalent to 53 IU/1. 
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desensitisation was, however, not as great as that in cells 
that were initially incubated with GnRH in the presence of 
Ca2 + . The human pituitary cells were not desens i tised to 
GnRH when the initial incubation was carried out with a GnRH 
antagonist (Fig. 3.7 A and B). 
Effect of pulsatile 
administration of GnRH on LH 
and FSH secretory profiles 
The administration of 4 min pulses of GnRH at varying 
pulse intervals of 45 min, 90 min and 180 min resulted in 
similar profiles of LH (Fig. 3.8A) and FSH (Fig. 3.8B) 
secretion. After three repeated pulses of GnRH, however, the 
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Fig. 3.8 Effect of 4 min pulses of GnRH, administered at 
pulse frequencies of 45 min, 90 min and 180 min, on LH (A) 
and FSH (B) secretion from cultured human pituitary cells. 
All values represent mean ± SEM of triplicate incubations 
using pooled pituitary tissue from 2 cadavers. Basal values 
were subtracted from GnRH-stimulated values in each case. 
1 ng/100 ul/min LH is equivalent to 2.77 IU/1/min and 1 ng/ 
100 ul/min FSH is equivalent to 0.53 IU/1/min. 
78 
DISCUSSION 
Human pituitary cells dispersed from glands obtained at 
autopsy and cultured for 3 to 4 days released LH and FSH, 
TSH and PRL, GH and ACTH in response to 100 nM doses of 
GnRH, TRH, GHRH and CRH, respectively. When the releasing 
hormones were added simultaneously, the release of TSH was 
greater than that stimulated by TRH alone, suggesting that a 
releasing hormone other than TRH can augment the response to 
TRH. This was not investigated further as it is beyond the 
scope of this thesis. 
GnRH stimulated LH release from human pituitary cells 
in a dose dependent manner, the EC~o being 0.95 nM, which is 
of the same order of magnitude as that for the rat (2.0 nM) 
in this and previous studies (Loumaye and Catt, 1983; Leiser 
et al., 1986). The human pituitary GnRH receptor has 
previously been found in our laboratory, to have a similar 
Kc:. for GnRH as the rat receptor (Wormald et al., 1985; 
chapter 2). GnRH agonists 1 and 2, chicken GnRH II were as 
active in stimulating LH release from human pituitary cells 
as from the rat. GnRH agonists 3 and 4, however, were more 
active in the human than in the rat, while GnRH antagonists 
1, 2 and 3 were less active in the human pituitary bioassay 
than in the rat. 
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There are therefore definite differences between the 
human and rat GnRH receptors which involve not only the 
ability of the receptors to recognise and bind different 
GnRH analogues, but also their ability to be activated by 
these analogues. 
bound the human 
For example, chicken GnRH II and agonist 2 
GnRH receptor with relatively poor 
affinities compared with the rat, but were as active in 
stimulating gonadotropin release in the human as in the rat. 
Recent studies carried out in our laboratory have 
demonstrated that the sheep GnRH receptor shares these 
characteristics of the human receptor for binding and being 
activated by these two particular analogues (unpublished 
data). Further differences between the human and rat 
receptors are evident from these bioassay data: GnRH 
agonists 3 and 4 bound both human and rat receptors with a 
similar affinities but were relatively poor agonists in the 
rat; GnRH antagonists 2 and 3 bound the human receptor with 
lower affinities than those of the rat and consequently were 
less active in inhibiting GnRH-stimulated gonadotropin 
secretion from human pituitary cells than from rat, although 
GnRH antagonist 2 was not as active in the rat as predicted 
from receptor studies; GnRH antagonist 1. although bound by 
the human and rat receptors with similar affinities. was a 
relatively poor antagonist in the human. 
Receptor binding studies and bioassays using animal 
tissue are therefore not always good predictors of GnRH 
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analogue activity in man. The establishment of a system for 
culturing functionally active human pituitary cells may thus 
be of greater use in the selection of GnRH analogues for 
clinical use. 
Stimulation with 100 nM GnRH resulted in a biphasic 
release of both LH and FSH from the cultured human pituitary 
cells. The lesser response of the human gonadotropes to GnRH 
after the initial brisk response was apparently not due 
entirely to depletion of gonadotropin stores since these 
cells then responded somewhat to Ca2 +-ionophore. The 
demonstration of decreased cellular LH and FSH content in 
the 4 h GnRH stimulation studies, however, suggests that 
gonadotropin depletion may have contributed to the 
diminished response in the 60 min study. The kinetics of LH 
secretion in the human are similar to what has been observed 
in the chicken and in the rat (Smith et al., 1987; Davidson 
et al., 1988). The kinetics of both LH and FSH release from 
human pituitary cells were identical, in contrast to in vivo 
studies where the rise in FSH in response to GnRH 
administration is slower but longer lasting than that of LH 
(Millar et al . , 1982). This is most likely due to the 
modulatory effects of gonadal hormones and inhibin. Kinetic 
considerations. such as the longer half life of FSH. cannot 
account for the slower rise in FSH. 
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GnRH-stimulated gonadotropin secretion from the human 
pituitary was Ca2 ·-dependent. since release was inhibited by 
the presence of 3 mM EGTA. as demonstrated earlier in rat 
(Bates and Conn. 1984; Limor et al .. 1987). chicken 
(Davidson et al .. 1987) and sheep (Magness et al .. 1981) 
gonadotropes. The Ca2 +-ionophore. A23187, caused significant 
gonadotropin release, indicating that an influx of 
extracellular Ca2 · ... will elicit gonadotropin secretion by 
human. as well as rat (Bates and Conn, 1984; Limor et al .. 
1987) and chicken (Davidson et al .. 1987) gonadotropes. The 
phorbol ester. TPA. an activator of protein kinase C. also 
caused significant LH and FSH release. suggesting that 
phospholipid turnover is a component in the mechanism of 
gonadotropin secretion. Limitations on availability of human 
material did not allow in depth studies but the data 
indicate that the human gonadotrope has similar signal 
transduction systems to those defined in the rat (Conn. 
1986). 
Incubation of the human pituitary cells for 3 h with 
dbcAMP resulted in a specific. dose-dependent increase in LH 
and FSH secretion. Although the kinetics of this effect were 
not investigated, this finding is in accordance with what 
has previously been found in the sheep (Magness et al .. 
1981) and more recently in the rat (Turgeon and Waring, 
1986; Bourne and Baldwin, 1987a; Bourne and Baldwin, 1987b) 
that cAMP, while not involved in the acute phase of LH and 
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FSH release, appears to play a pivotal role in the second 
phase of release by stimulating de novo synthesis. 
The human pituitary cells became less sensitive during 
prolonged stimulation with GnRH. This phenomenon of 
pituitary desensitization may be due to down-regulation of 
GnRH receptors after binding GnRH (Zilberstein et al., 
1983), uncoupling of post-receptor mediating mechanisms 
(Keri et al., 1983; Smith et al., 1983), or due to depletion 
of certain cellular LH and FSH stores. It is likely that 
depletion of gonadotropin stores does contribute to this 
phenomenon, since following stimulation with 100 nM GnRH 
total cellular LH was reduced to 52% and FSH to 51% of that 
of the unstimulated cells. In a separate experiment, when 
the initial incubation with GnRH was carried out under Ca2 +-
free conditions (i.e. under conditions where GnRH receptor 
binding occurs with no LH or FSH release), the cells still 
became desensitised to a subsequent stimulation with GnRH. 
The degree of desensitisation was, however, not as great as 
that in cells that were initially incubated with GnRH in the 
presence of Ca2 + suggesting 
I 
that the desensitisation 
phenomenon under normal conditions is partly due to 
depletion of intracellular stores of LH and FSH, and partly 
due to some other Ca2 +-independent mechanism. The human 
pituitary cells were not desensitised to GnRH when the 
initial incubation was carried out with a GnRH antagonist, 
indicating that desensitisation requires receptor activation 
in addition to receptor occupancy. Studies on GnRH-induced 
desensitisation in other mammalian (Smith and Vale, 1981; 
Keri et al., 1983; Smith and Conn, 1983; Conn et al., 1982a; 
Conn et al., 1982b) and chicken (King et al., 1986) 
pituitary cells have shown that desensitisation requires 
receptor microaggregation and internalisation and that 
receptor occupancy by GnRH antagonists is not sufficient to 
produce desensitisation. 
It has been well documented that variations in GnRH 
pulse frequency in vivo alter the ratio of LH to FSH 
released from the pituitary (Wildt et al., 1981; Clarke et 
al., 1984; Gross et al., 1987). In order to determine 
whether LH and FSH can be controlled differentially by 
varying the pattern of GnRH stimulation alone, free of the 
effects of other regulatory hormones which are present in 
vivo, cultured human pituitary cells were pulsed with 4 min 
pulses of 3 nM GnRH at varying frequencies of 45 min, 90 min 
and 180 min. The cells became desensitised to GnRH after 2 
pulses and failed to respond after the third. In rats it has 
been shown that pulsing perifused pituitary cells with low 
doses of GnRH results in stabilisation of the cells which 
are capable of responding to the releasing hormone for up to 
24 h (Liu and Jackson, 1984). The human pituitary cells thus 
appear to be unable to synthesise new stores of LH and FSH. 
The cells are also not able to undergo self-priming by low 
doses of GnRH (data not shown) as has been described in 
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animal cells (Morris et al., 1986). This is possibly due to 
post-mortem changes in the tissue, since the human pituitary 
cells are not cultured immediately after death , as are 
animal cells, but anything from 6 to 24 h later. 
Alternatively, this phenomenon may merely be a 
characteristic of the static culture system. 
These studies have established that human pituitary 
tissue, obtained within 24 hours of autopsy, may be cultured 
for 3 to 4 days and stimulated with the hypothalamic 
releasing hormones to secrete LH, FSH, TSH, PRL, GH and 
ACTH. Human gonadotropes are similar to those of the rat in 
their response to GnRH and a number of GnRH analogues, but 
differed in their response to two GnRH agonists and three 
GnRH antagonists. These results support our previous 
contention, from receptor binding studies (Wormald et al., 
1985), that rat gonadotropes may not be useful for studying 
GnRH analogue activity to identify superactive analogs for 
use in human studies. 
This system of culturing human pituitary cells from 
autopsy tissue is likely to be particularly useful for 
investigating the regulation of gonadotropic hormone 
secretion in man. 
CHAPTER 4 
OTHER PEPTIDE REGULATORS OF 
GONADOTROPIN SECRETION 
SECTION 1 
NOVEL PEPTIDE REGULATORS WITHIN THE 
HUMAN GnRH PROHORMONE 
85 
INTRODUCTION 
GnRH is synthesised and secreted by hypothalamic 
neurons. Although in early reports an enzyme template 
mechanism was suggested to underlie the biosynthesis of GnRH 
(Johansson et al.,1972; Johansson et al., 1973), the 
identification of higher molecular weight immunoreactive 
GnRH in sheep and pig hypothalamus (Millar et al. , 1977; 
Millar et al. , 1978; Millar et al., 1981) and human placenta 
(Gautron et al., 1981) implicated conventional ribosomal 
biosynthesis 
supported by 
of a prohormonal form. This was further 
the in vivo demonstration of hypothalamic GnRH 
biosynthesis (Kochman et al., 1982) and by precipitation of 
the products of reticulocyte lysate translation of rat, 
mouse and human hypothalamic mRNA by GnRH antiserum (Curtis 
and Fink, 1983; Curtis et al., 1983). Millar et al. proposed 
that the amino-terminal pGlu residue of GnRH was derived 
from Gln while the Gly-Nlk of the carboxvl terminus resulted 
from the enzymic processing of a Gly followed by a pair of 
basic amino acids which constitute the beginning of the 
carboxyl-terminal extension of the prohormonal precursor, as 
is the case with other amidated peptides (Douglass et al., 
1984). This prediction has been confirmed by the elucidation 
of the nucleotide sequences of human placental GnRH cDNA 
(Seeburg and Adelman, 1984) and human hypothalamic GnRH cDNA 
(identical to 
cDNA (exibits 
placental cDNA) as well as rat hypothalamic 
70% homology with human) (Adelman et al., 
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1986). The GnRH sequence is followed by a cleavage and 
amidation site (Gly-Lys-Arg) and then a 53-amino acid 
sequence and a second potential cleavage site (Lys-Lys-Ile) 
(Fig. 1). In addition to cleavages at these pairs of basic 
amino acid residues, processing may occur at single basic 
amino acids, especially arginine (Fig. 1), as such cleavages 
occur in several peptide precursors (Douglass et al., 1984). 
Since post-translational processing of several peptide 
precursors gives rise to different peptide fragments with 
various biological functions (Douglass et al., 1984), it was 
of interest to determine whether this is also true of the 
GnRH precursor. A number of overlapping peptide sequences, 
which lie between putative basic amino acid processing 
sites, were therefore synthesised in our laboratory and 
tested in the human pituitary bioassay system. These 
peptides have been designated pHGnRH for precursor Human 
GnRH, followed by the amino acid numbering as assigned by 
Seeburg and Adelman (1984). 
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MATERIALS AND METHODS 
Peptides 
Synthetic GnRH and precursor peptides: pHGnRH 14-26, 
pHGnRH 17-26, pHGnRH 14-36, pHGnRH 17-36, pHGnRH 14-37, 
pHGnRH 17-37, pHGnRH 28-36, pHGnRH 38-49, pHGnRH 51-66 and 
pHGnRH 54-66 were synthesised by Dr R deL Milton (Fig. 
4.1.1) using conventional solid phase methodology (Stewart 
and Young, 1984); GnRH-associated peptide (GAP) was from Dr 
P Seeburg, Genentech Inc. (South San Francisco, CA). 
PRE 
-23 
GnRH CS CARBOXYL - TERMINAL EXTENSION PCS -1 1 10 11 14 









46 50 53 66 67 68 69 
Arg Arg Lys 4'S 4'S lie 
38 49 
51 66 
Fig. 4.1.1. Diagramatic representation of human pre-pro GnRH. The signal sequence (PRE) is followed by the GnRH sequence and the Lys-Arg cleavage site (CS). Single basic amino acid residues which may be additional post-translational processing sites are indicated in the carboxYl-terminal extension, and the second potential cleavage site (PCS) precedes the carboxyl-terminal isoleucine residue. Glu1 undergoes cyclisation to pGlu at the amino-terminus of GnRH, and Gly11 is the donor for amidation of Gly10 during the processing of the GnRH precursor. The open bars represent five of the pHGnRH peptides synthesised. 
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Preparation of cells 
Human anterior pituitary glands were obtained at 
autopsy from healthy men (16-40 years old) between 11 and 18 
h after traumatic accidental death and were processed as 
described in Chapter 3. 
Incubation of cells 
After 3 to 4 days in culture, the cells were washed 5 
times with MEM, and test peptides added to duplicate or 
triplicate wells. After 3 hours of incubation the medium was 
removed, collected into tubes containing BSA, to prevent 
absorption of gonadotropins, such that the final 
concentration of BSA was 0.1%, centrifuged at 400xg for 5 
min, and stored at -20°C until assay for LH, FSH and 
prolactin . 
. Receptor bindi~g studies 
Human anterior pituitaries were obtained from 1 woman 
(45 yr of age) and 2 men (20-26 yr of age) within 24 h of 
accidental death. Pituitary membranes were prepared as 
previously described (Wormald et al., 1985; Chapter 2), with 
the exception that the membrane suspension used was 2-fold 
more concentrated (0.2 human pituitary equivalents/ ml). 





Gonadotropin- releasing activity was associated with 
five of the pHGnRH peptides. viz. pHGnRH 14-26. pHGnRH 14-
36, pHGnRH 17-36. [Arg::.~: 7 NH~~ 1 pHGnRH 14-37 and 
(Arg::!: 7 NH~ ] pHGnRH 17-37 (Fig. 4 .1. 2. expt. 1) . These peptides 
consistently gave rise to a significantly (p<0.05! greater 
than basal LH and FSH release (in seven experiments). pHGnRH 
28-36 consistently (in five experiments) failed to stimulate 
greater than basal LH and FSH release !Fig. 4.1.2. expt. 1). 
pHGnRH 17- 26 significantly stimulated LH (p<0.01) and FSH 
(p<0.05) in two out of four experiments (Fig. 4.1.2. expt. 
2). The active pHGnRH peptides did not stimulate secretion 
of prolactin or TSH from the human pituitary cell cultures 
( Tab 1 e 4 . 1 . 1 ) . 
pHGnRH 14-36 stimulated LH and FSH release in a dose 
dependent manner. the EC~.::, for LH being 178nM (Fig. 4.1.3 
Al. and for FSH 200nM (Fig. 4.1.3 Bl. which is more than 
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Fig. 4.1.2. Gonadotropin release from cultured human pituitary cells stimulated with pHGnRH peptides. Data from two experiments are presented. All the pHGnRH peptides tested, except pHGnRH 17-26 and pHGnRH 28-36, were consistently associated with significant gonadotropin release (expt. 1). The longer sequences (>20-amino acid residues) were approximately 10-fold more active than the shorter peptides (<15-amino acid residues). pHGnRH 17-26 stimulated gonadotropin secretion from certain pituitary cell cultures (expt. 2) but not from others (expt. 1), while pHGnRH 28-36 was consistently unable to stimulate gonadotropin release (expt. 1). 
All values represent mean ± SEM of triplicate 3 h incubations using pooled pituitary tissue from 4 cadavers for expt. 1, and from 5 cadavers for expt. 2. Significantly different from basal values; * p<0.05, ** p<0.01, *** p<0.001 as determined by analysis of variance. 
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Fig. 4.1.3. Dose-responsive gonadotropin secretion from cultured human pituitary cells stimulated with pHGnRH 14-36. pHGnRH 14-36 stimulated LH (A) and FSH (B) release in a dose-dependent manner, the E~o for LH release being 178 nM and for FSH 200 nM. 
All values represent mean± SEM of duplicate 3 h incubations using pooled pituitary tissue from 2 cadavers. 
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TABLE 4.1.1. Effect of pHGnRH peptides on prolactin and TSH 
secretion from cultured human pituitary cells 
Basal 
l0- 6 M GnRH 
10-:5M pHGnRH 14-26 
10- 6 M pHGnRH 14-36 
l0- 6 M pHGnRH 17-36 
Al 1 values 




11.3 ± 0.45 
11. 2 ± 0.75 
10.2 .± 0.50 
10.8 + 0.92 
9.0 ± 0.21 
represent mean ± SEM 
TSH secretion 
(uU/ml) 
3.1 ± 0.75 
2.9 .± 0.30 
3.2 ± 0.65 
2.8 + 0.64 
3.1 .± 0.26 
of dup 1 icate 






pHGnRH 14-36 - stimulated LH and FSH release was Ca2 +-
dependent (Fig. 4.1.4). In the presence of extracellular 
Ca2 + both GnRH and pHGnRH 14-36 stimulated significant 
(p<0.01) gonadotropin secretion while in the presence of 3mM 
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Fig. 4.1.4. The effect of EGTA on the gonadotropin release from cultured human pituitary cells stimulated by pHGnRH 14-36. The presence of 3 mM EGTA significantly reduced both the LH and FSH release stimulated by pHGnRH 14-36 to near basal values. 
All values represent mean± SEM of duplicate 3 h incubations using pooled pituitary tissue from 3 cadavers. Significantly different from basal values; * p(0.05, ** p(0.01, *** p(0.001 as determined by analysis of variance. 
Significantly different from pHGnRH 14-36 stimulated gonadotropin release; ++ p(0.01, +++ p(0.001 as determined by analysis of variance. 
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Effect of pHGnRH peptides on 
i.-ncorporation. 
The precursor peptides, pHGnRH 14-26, pHGnRH 14-36 and 
pHGnRH 17-36, had no effect on (3 H]-leucine incorporation in 
cultured human pituitary cells when compared with basal or 
unstimulated eel ls (Table 4.1. 2). 
TABLE 4.1.2. Effect of pHGnRH peptides on [ 3 H]-leucine incorporation in cultured human pituitary cells 
Treatment 
Basal 
1Q- 5 M pHGnRH 14-26 
10-5 M pHGnRH 14-36 
lQ- 5 M pHGnRH 17-36 
(
3 H]-Leu incorporation 
(% basal) 
100.0 ± 3.8 
106.2 ± 3.2 
99.9 + 2.6 
93.4 + 2.7 
All values represent mean± SEM of triplicate 3 h incubations using pooled cells from 2 cadavers. 
Effect of a Gn.RH antagonist on 
pHGnRH-stim~1ated gonadotropin 
re1ease 
GnRH antagonist 3 (see Chapters 2 and 3), at a dose of 
l0- 6 M, completely inhibited both 10- ~M pHGnRH 14-26 - (Fig . 
4.1.5, expt. 1) and 10- 6 M pHGnRH 14-36 - stimulated LH and 
FSH release (Fig. 4.1.5, expt. 2). 
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EXPERIMENT 1. EXPERIMENT 2. 
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Fig. 4.1.5. The effect of a GnRH antagonist on pHGnRH 14-26 and pHGnRH 14-36 - stimulated gonadotropin secretion from cultured human pituitary cells. Data from two experiments are presented. GnRH antagonist 3, at a dose of 10- 6 M, inhibited 10- aM GnRH- and l0- 6 M pHGnRH 14-36 - stimulated gonadotropin secretion (expt. 1) and 5x10- 0 M pHGnRH 14-26 -stimulated release (expt. 2). 
All values represent mean± SEM of duplicate and triplicate 3 h incubations using pooled pituitary tissue from 2 cadavers for expt. 1, and 5 cadavers for expt. 2. Significantly different from GnRH-stimulated gonadotropin secretion;* p<0.01, ** p<0.001 as determined by analysis of variance. 
Significantly different from pHGnRH 14-36 stimulated gonadotropin secretion; (1 star) p<0.01, (2 stars) p(0.001 as determined by analysis of variance. Significantly different from pHGnRH 14-26 stimulated gonadotropin secretion; # p(0.01 as determined by analysis of variance. 
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Effect of pHGnRH 14-36 on 
[ 1 ==I]-GnRH agonist binding to 
human pituitary membranes 
pHGnRH 14-36 competed with the [1 23 I]-GnRH agonist. [D-
Ala0,N~MeLeu7,Pro9NEt]-GnRH, for binding to human pituitary 
cell membranes (Fig. 4.1.6). The presence of 1Q- 4 M pHGnRH 
14-36 in the human GnRH receptor binding assay reduced 
binding of the labelled GnRH agonist to 32.8 ± 0.2 % of 
control values. pHGnRH 14-26 (5x10- ~M) also competed for 
binding to the GnRH receptor (Fig. 4.1.6). although to a 
much lesser degree than pHGnRH 14-36. 
The combined effect of pHGnRH 
14-36 and GnRH on gonadotropin 
secretion 
10- 0 M GnRH and 10-·0 M pHGnRH 14-36 significantly 
stimulated LH (Fig. 4.1.7 A) and FSH (Fig. 4.1.7 B) release. 
Co-stimulation of the cultured 
GnRH and pHGnRH 14-36 did not 
release of gonadotropins, above 
alone (Fig. 4 .1. 7) . 
human pituitary cells with 
result in any additional 
that stimulated by GnRH 
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Fig. 4.1.6. Displacement of [ 125 1)-GnRH agonist from human pituitary membranes by increasing concentrations of GnRH, pHGnRH 14-36 and pHGnRH 14-26. pHGnRH 14-36 displaced the labelled GnRH agonist with an ED~o of 3.98x10-~ M. pHGnRH 14-26 was less active than pHGnRH 14-36 , displacing only 10% of the label at a dose of 5x1Q- 5 M. 
All values represent mean ± SEM of triplicate incubations using pooled pituitary membranes from 3 cadavers . 
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Fig . 4.1.7. Effect of GnRH and pHGnRH 14-36 on LH and FSH release from cultured human pituitary cells, when added alone or in combination. pHGnRH 14-36 , at a dose of 10-~M. did not stimulate any additional release of LH (A) or FSH (B) above that stimulated by l0- 0 M GnRH. All values represent mean ± SEM of triplicate 3 h i ncubations using pooled pituitary tissue from 2 cadavers. 
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DISCUSSION 
The elucidation of the structure of the human GnRH 
precursor (Seeburg and Adelman, 1984) has provided 
information for a wide range of studies on the regulation of 
the reproductive system. In view of the precedent of some 
hormone precursors giving rise to several processed peptides 
with different biological activities (Douglass et al .. 1984) 
it was of interest to determine whether the same is true for 
the GnRH precursor. 
A series of ten overlapping peptide sequences, which 
are potentially processed from the human GnRH precursor, 
were synthesised and tested in the human pituitary bioassay 
system for biological activity (Fig. 4.1.1). Five of these 
peptides (pHGnRH 14-26, pHGnRH 14-36, pHGnRH 17-36, 
[Arg37 .Nlk]-pHGnRH 14-37 and [Arif!'' .Nlk]-pHGnRH 17-37) 
consistently, on seven independent occasions, gave rise to 
significantly greater than basal LH and FSH release. The 
peptide fragment, pHGnRH 28-36, consistently (in five 
experiments) failed to stimulate gonadotropin secretion. 
Each of the active overlapping peptides incorporates the 
decapeptide sequence, Asn-Leu-lle-Asp-Ser-Phe-Gln-Glu-Ile-
Val, corresponding to pHGnRH 17-26 which is therefore 
considered to represent a defined region of the GnRH 
precursor with intrinsic gonadotropin-releasing activity. 
This peptide fragment was therefore also synthesised and 
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tested for gonadotropin-releasing activity. pHGnRH 17-26 
significantly stimulated LH and FSH release from different 
cell cultures in two out of four experiments. In the 
remaining two experiments this decapeptide fragment did not 
significantly stimulate gonadotropin release, although GnRH 
and pHGnRH 14-26 included in the same experiments did 
stimulate gonadotropin secretion. A 5-fold higher 
17-26 (and pHGnRH 14-26), in 
concentration of pHGnRH 
comparison to the other active peptides, was required to 
stimulate gonadotropin release. The relatively low and 
inconsistent activity of pHGnRH 17-26 suggests that this 
peptide fragment approaches the minimal sequence required 
release. The increased activity associated 
for gonadotropin 







minimal sequence, stresses the 
flanking sequence has on 
gonadotropin-releasing activity. This is also in accordance 
with that which has been reported by Nikolics et al. (1985); 
that the entire C-terminal extension , pHGnRH 14-69 or GAP 
(GnRH associated peptide), stimulated LH and FSH release 
from rat pituitary cells with a similar or greater potency 
than GnRH. Other synthetic peptides covering the remainder 
of the GnRH precursor sequence (pHGnRH 38-49, pHGnRH 51-66 
and pHGnRH 54-66) did not exhibit gonadotropin releasing 
activity (data not shown), although a complete series of 
overlapping fragments has not been synthesised. 
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pHGnRH-stimulated gonadotropin secretion from the 
cultured human pituitary cells was dose-dependent. The 
active peptides were, however, at least 300-fold less active 
than GnRH and in most experiments did not achieve the same 
maximum release of LH and FSH as GnRH. This effect of these 
peptides was specific in that prolactin and thyrotropin 
concentrations in the medium were unaffected. Also, LH and 
FSH release in response to these peptides did not occur in 
the absence of extracellular calcium. The removal of calcium 
ions by chelation with EGTA significantly reduced the LH and 
FSH release, stimulated by pHGnRH 14-36, to near basal 
levels. Further evidence that these effects of the pHGnRH 
peptides are specific comes from the study showing that 
incorporation of [3 H]-Leu into protein by the cells was 
unaffected by the presence of the peptides. 
In view of the lack of structural homology between the 
active pHGnRH peptide fragments and GnRH itself, it was of 





these different peptides was mediated by a 
on the pituitary gonadotrophs. The GnRH 
[Ac-D-Nal(2) 1 ,D-a-Me-ClPhe2 ,D-Trp3 ,D-Ar9"",D-
which competetively inhibited GnRH-
stimulated gonadotropin secretion from the cultured human 
pituitary cells, also blocked the release of LH and FSH 
associated with both pHGnRH 14-26 and pHGnRH 14-36. This 
indicates that the active pHGnRH peptides stimulate the 
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gonadotrophs via the GnRH receptor. We initially reported 
that the GnRH antagonist was not able to prevent pHGnRH-
stimulated gonadotropin secretion (Millar et al ., 1986b: 
Milton et al., 1986). These early experiments, however, were 
carried out under sub-optimum conditions, whereby, following 
stimulation of the cultured cells, BSA was not added to the 
collection tubes. This resulted in approximately 90% loss of 
LH and FSH from the medium due to nonspecific adherence of 
the hormones to the walls of the tubes. 
Further evidence that active pHGnRH peptides stimulate 
gonadotropin release via the GnRH receptor 
GnRH receptor binding studies. pHGnRH 
is provided by 
14-36 displaced 
[ 1 2 0 I ] -1 abe 11 ed GnRH agonist, from human 
membranes, with approximately 10,000-fold 





5x10- 0 M 
displaced only 10% of the label from the receptor, while 
pHGnRH 14-36, at the same dose, displaced almost 60%. pHGnRH 
14-26 was similarly less active than the longer peptides in 
the bioassay . There is 
ability of pHGnRH 14-36 
fold less active than 
and FSH (300-fold less 
an apparent discrepancy between the 
to bind the GnRH receptor (10,000-
GnRH) and its ability to release LH 
active than GnRH). This phenomenon 
has also been observed with weak GnRH agonists (Hasegawa et 
al., 1984: Millar et al., 1986a) and may merely reflect the 
poor ability of these weak agonists to compete with the 
labelled superactive agonist for binding, whereas in the 
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bioassay, which is a noncompetitive system, activity is 
directly dependent on receptor affinity. 
In view of the fact that the active pHGnRH peptides 
stimulate gonadotropin secretion via a similar mechanism to 
GnRH, it was important to exclude the possibility of 
contamination of these peptides 
Analytical reverse phase 




chromatography fractionation of pHGnRH 14-36, under 
conditions in which pHGnRH 14-36 eluted later than GnRH and 
GnRH analogues synthesised in our laboratory, showed that 
the LR-releasing activity in rat cells and receptor binding 
activity to rat pituitary membranes coincided with the 
pHGnRH 14-36 UV absorption peak (Milton et al., 1987). 
Further evidence against contamination is provided by the 
fact that pHGnRH 14-26 was active in the human bioassay but 
not in the rat (Milton et al., 1987). Only pHGnRH 14-36 and 
longer peptides were active in stimulating LH release from 
cultured rat pituitary cells (data not shown). 
pHGnRH 14-36, when added to the human pituitay cells 
with GnRH, could not stimulate gonadotropin release above 
the maximum released by GnRH. No evidence of synergistic or 
antagonistic effects was observed. Similarly, there was no 
additive effect with GAP (pHGnRH 14-69) and GnRH in rat 
pituitary cell cultures (Nikolics et al., 1985). These 
observations indicate that the same cell was activated by 
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both GnRH and the pHGnRH peptides, and that pHGnRH 14-36 
stimulated LH and FSH release from a common intracellular 
pool. The biphasic nature of gonadotropin secretion in 
response to GnRH (see Chapter 3, Fig. 3.4; Naor et al., 
1982; King et al., 1986), however, suggests that there may 
be different cellular pools of LH and FSH, and since the 
pHGnRH peptides (in most experiments) did not stimulate the 
same maximum release of gonadotropins as that acheived by 
GnRH, this suggests that these peptides are not capable of 
activating all the cellular LH and FSH pools which are 
activated by GnRH. This provides further evidence against 
the argument for GnRH contamination of the active pHGnRH 
peptides. 
Further work is required to establish whether any of 
the pHGnRH peptide fragments have a physiological role in 
gonadotropin secretion. In particular, it is necessary to 
demonstrate that the active peptide/sis secreted into the 
hypophyseal-portal vessels at concentrations capable of 
stimulating gonadotropin secretion, and that the 
administration of an antiserum to the peptide inhibits 
gonadotropin secretion in vivo. Whether these peptides 
fulfill a physiological role or not, it is evident that 
synthetic pHGnRH peptides incorporating the sequence 17-26 
and the full 56-amino acid peptide (pHGnRH 14-69 or GAP) 
(Nikolics et al., 1985) do release gonadotropin and so offer 
the potential for the development of a new range of 
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Substance P (SP) is an undecapeptide which is widely 
distributed within the peripheral and central nervous 
systems of mammals (Nicholl et al., 1980: Aronin et al., 
1983; Pernow, 1983), and has been implicated as a regulatory 
peptide in the control of reproductive function (Kerdelhue 
et al., 1978; Vijayan and Mccann, 1979; Eckstein et al., 
1980). SP has been found to inhibit GnRH-stimulated LH and 
FSH release from cultured rat anterior pituitary cells 
(Kerdelhue et al., 1979; Kerdelhue et al., 1982) and to bind 
to specific high affinity binding sites in rat anterior 
membranes (Kerdelhue et al., 1982; Kerdelhue et al., 1985), 
suggesting a direct modulatory role for SP on GnRH 
stimulation of gonadotropin secretion. More direct evidence 
for a physiological role of SP is provided by the 
observation of an increase in LH and FSH after 
ad.ministration of SP antisera to rats (Kerdelhue et al., 
1979; Kerdelhue et al., 1982). SP, when ad.ministered to 
female rhesus monkeys, however, had no effect on 
gonadotropins (Eckstein et al., 1980), suggesting that the 
peptide may not play a role in the control of reproduction 
in primates. 
In view of these findings, I have investigated the 
presence of specific SP receptors in the human pituitary and 
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the effect of SP on GnRH-stimulation of LH and FSH release 
from cultured human anterior pituitary cells. 
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MATERIALS AND METHODS 
Ho ::r-mo n es 
Synthetic SP was obtained from UCB s.a., (Bruxelles, 
Belgium); SP analogues [D-Tyr0 J-SP, [D-Tyr',NorLeu11 J-SP, 
SP(3-ll), SP(7-10), SP(5-8) and SP(l-4) were from Dr B 
Kerdelhue, INRA CNRS (Jouy-en-Josas, France); and synthetic 
TRH and GnRH were from Dr R deL Milton, University of Cape 
Town Medical School (Cape Town, South Africa). 
Bind.. i ng st l...l.d.. i es 
Human anterior pituitaries were obtained from twelve 
healthy men (20-40 years old) within 24 h after accidental 
death and stored at -70CC until use. The tissue was 
homogenised in buffer A (lOmM HEPES, lmM EDTA, lmM 
dithiothreitol, 0.1% BSA, 10- :!.M bacitracin, pH 7 .4) 
centrifuged at l, 000 X g for 15 min and the resulting 
supernatant at 10,000 X g for 30 min. The membrane pellet 
was resuspended in the same buffer. Al 1 binding studies were 
performed in triplicate as previously described in Chapter 
2. Total binding (5.33-11.64%) was determined in the absence 
of unlabelled peptide and nonspecific binding (3.73-8.90%) 
by the addition of 10-0 M SP or analogue. 
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.[D-Tyr0 ,NorLeu11 ]-SP was labelled with Na12!5I 
(Kerdelhue et al., 1973) and purified by QAE Sephadex A-25 
chromatography (Nett and Adams, 1977) (specific activity 800 
uCi/ug). Kds were estimated from Scatchard analysis and from 
ED~o values using the formula of Cheng and Prusoff (1973). 
the cells 
Human anterior pituitaries were obtained at autopsy 
from 16 healthy men (25-35 years old) between 6 and 24 h 
after accidental death, and processed as previously 
described in Chapter 3. 
Incubation of the ce11s 
After 3 days in culture, the cells were washed 5 times 
with minimal essential medium (MEM) and the test substances 
added in triplicate. After a 3 h incubation the medium was 
removed, centrifuged at 400 x g for 5 min and the 
supernatant assayed for LH and FSH. 
Radioimmunoassays 
Assays were performed 
radioimmunoassay (Amerlex LH 
Amersham; intra-assay c.v. 
in duplicate using a human LH 
RIA kit code IM 2081, 
3.2%) and a human FSH 
110 
radioimmunoassay (Amerlex FSH RIA kit 
Amersham; intra-assay c.v. 6.2%) 
code IM 2071, 
1 1 1 
RESULTS 
SP binding to human pituitary 
cell membranes 
Binding of 12~I-[D-Tyr0 ,NorLeu11 ]-SP to human anterior 
pituitary membranes was progressively inhibited by the 
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Fig. 4.2.1 Displacement of [12~1]-labelled [D-Tyr=', NorLeu11 J-SP binding to human pituitary membranes by unlabelled SP (e), [D-Tyr0 J-SP (*), [D-Tyr=',NorLeu11 J-SP (0) SP(3-11) ( D), SP(7-10) C•), SP(5-8) ( t:..), SP(l-4) ( v), 
TRH C•) and GnRH (T). 
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4.2.1). Scatchard analysis (Fig. 4.2.2) indicated that the 
binding was saturable and involved a single class of high 
affinity sites (Kd of 19.3 nM). The binding affinities of 
SP, [D-Tyrc,]-SP and [D-Tyr',NorLeu11 ]-SP were similar (~s 
of 17.6 nM, 35.3 nM and 19.3 nM respectively) while the 
shorter fragments of SP exhibited lower binding affinities 
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Fig. 4.2.2 Scatchard analysis of the binding of [D-Tyr', 
NorLeu11 ]-SP to human pituitary membranes. 
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TABLE 4.2.1. Apparent dissociation constants of SP analogues and fragments, and other unrelated peptides, binding to human pituitary membranes 
K.::t (~) 
Substance P 17.6 + 2.9 
[D-Tyr0 ]-SP 35.3 + 18.5 
[D-Tyr0 ,NorLeu11 ]-SP 19 . 3 + 3.0 
SP(3-11) 92.4 + 8.4 
SP(7-10) 286.0 + 42.0 
SP(5-8) > 1000 
SP(l-4) > 1000 
GnRH > 1000 
TRH > 1000 
All values represent mean± SEM of binding studies carried out in triplicate using pooled membranes from 6 cadavers. Kos were calculated by Scatchard analysis for [D-Tyr0 ,NorLeu11 ]-SP and by the method of Cheng and Prusoff (1973) for SP, [D-Tyr0 ]-SP, SP(3-11) and SP(7-10). 
Effect of SP on GnRH-
stimulated LH and FSH ~elease 
Cultured human pituitary cells secreted both LH and FSH 
when stimulated with 1~- 6 M GnRH (Fig. 4.2.3). In one 
experiment, GnRH-stimulated LH secretion was progressively 
inhibited (p<0.05) by increasing concentrations of SP (Fig. 
4.2.3A). FSH release was also reduced in the presence of SP, 
but the difference was not significant (Fig 4.2.3B). In a 
second experiment 10- 6 M SP inhibited 3~ GnRH-stimulated LH 
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secretion .(data not shown) , while in three further 
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Fig. 4.2.3 The effect of 10-aM and 10-6 M SP on 10- 0 M GnRH-
stimulated LH and FSH secretion from cultured human 
pituitary cells. 
All values represent mean ± SEM 
incubation using pooled pituitary 
and were calculated as a percent of 
LH and FSH induced by GnRH. 
of a triplicate 3 h 
tissue from 3 cadavers, 
the specific increase in 
Control represents the specific increase over basal values, 
of LH and FSH, stimulated by 10- 6 M GnRH alone. 
* Significantly different from control value as determined 
by analysis of variance. 
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DISCUSSION 
Previous reports have suggested a modulatory role for 
SP in regulating gonadotropin secretion during the oestrus 
cycle of the rat (Kerdelhue et al .. 1982). SP has been found 
to affect the release of gonadotropins and prolactin in the 
rat. both in vivo (Kerdelhue et al .. 1978: Vi j ayan and 
Mccann. 1979) and in vitro (Kerdelhue 
has been further supported by the 
et al .. 1979) . This 
demonstration of SP 
binding sites in rat anterior pituitary membranes (Kerdelhue 
et al. , 1985) and by the observation that administration of 
SP antisera to rats results in elevated LH and FSH levels 
(Kerdelhue et al .. 1979 and 1982). The administration of SP 
to female rhesus monkeys induced a significant increase in 
prolactin secretion but had no effect on gonadotropins 
(Eckstein et al . . 1980) suggesting that the peptide does 
not play a significant role in the control of reproduction 
in primates . 
The present study has demonstrated the presence of a 
single class of saturable. specific. high affinity binding 
sites or receptors for SP in the human anterior pituitary. 
The binding characteristics of the human pituitary SP 
receptor were similar to those of the rat !Kerdelhue et al .. 
1985) . SP. [D-Tyr0 )-SP and (D- Tyr':,, NorLeu11 ) - SP had similar 
a f f i n i t i es ( Kr1 s of 17.6 nM. 35. 3 nM and 19.3 nM 
respectively) for the receptor. while the shorter fragments, 
1 16 
SPC3-11). SP(7-10). SP(5 - 8) and 
lower potencies IK~s of 92.4 nM . 
SP(l - 4) had 
286 nM. 
progressively 
>1 uM and >1 uM 
respectively). As amino acids are removed from the N- or C-
terminus of the molecule the binding affinity of the 
receptor for the peptide is diminished. 
SP directly inhibited LH secretion from the cultured 
human pituitary cells. This effect was observed on only two 
out of five occassions which is perhaps not surprising, 
since previous in vitro studies carried out in the rat 
showed that the inhibitory effect of SP was most pronounced 
in female pituitaries obtained at pro-oestrus when SP 
receptor number is high. suggesting that the phenomenon is 
steroid-dependent (Kerdelhue et al .. 19821. This study has 
nevertheless demonstrated that SP is capable of inhibiting 
gonadotropin secretion in the primate. 
The demonstration of a single class of high affinity, 
specific binding sites for SP and the inhibition by SP of 
gonadotropin secretion from cultured human pituitary cells. 
indicates that SP can act directly at a pituitary level in 
man and thus may play a regulatory role in the human 
reproductive cycle. The mechanism by which SP exerts its 
effect. however. has yet to be elucidated. 
CHAPTERS 




This thesis has investigated the binding 
characteristics of the human GnRH receptor and has 
demonstrated that it differs from the rat receptor in its 
interaction with at least four GnRH analogues , its ionic 
requirements for monovalent and divalent cations, and in the 
molecular size of the GnRH binding protein. This may have 
important clinical implications, since these data suggest 
that rat studies are not a valid index for GnRH analogue 
activity in man. 
A system for culturing human pituitary cells has been 
established and the data from these studies have further 
demonstrated that there is poor correlation, not only 
between the biological potencies of five GnRH analogues in 
humans and rats, but also between the receptor assay and the 
bioassay within a species (particularly in the human). The 
mechanism of GnRH action and the regulation of gonadotropin 
secretion, from the human pituitary cells, by substance P 
and a series of novel peptides putatively processed from the 
human GnRH precursor, however, was found to closely parallel 
that observed in the rat. 
These data support the previous contention, from 
receptor binding studies, that rat gonadotrophs are not 
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appropriate for investigating the activities of GnRH 
analogues for use in human studies. 
119 
FUTURE STUDIES 
In order to characterise the binding site of the human 
GnRH receptor in more detail, human receptor binding studies 
need to be carried out using a library of different GnRH 
analogues. In this way the region of the GnRH mo l ecule 
required for binding can be approximated, and some idea of 
the chemical nature of the binding site gained. 
The human bioassay system can also be exploited in 
order to investigate the regulation of gonadotropin 
secretion, in man, by other hormones and neurotransmitters. 
In particular the effects of the gonadal steroids, which 
have been shown in a number of animal models to affect 
gonadotropin secretion at the pituitary level by altering 
the responsiveness of the gonadotropes to GnRH; inhibin, 
which specifically inhibits FSH secretion from rat pituitary 
cells; the opioid peptides, which are capable of directly 
inhibiting GnRH-stimulated gonadotropin secretion in rats; 
and the catecholamines, which have been shown to potentiate 
the effect of GnRH on rat gonadotropes, should be 
investigated, thus providing more insight into the 
regulation of the human reproductive cycle. 
In addition to these studies, the human pituitary cell 
bioassay system can be extended to investigate the direct 
120 
regulation of the other pituitary hormones; TSH, prolactin, 
ACTH and GH, in man. 
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